BMJ
open

Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

SCHOLARONE™
Manuscripts

Title: Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

Authors:

Hironao Hozumi, M.D., Ph.D.[1]

Yutaro Nakamura, M.D., Ph.D.[1]

Takeshi Johkoh, M.D., Ph.D.[2]

Hiromitsu Sumikawa, M.D., Ph.D.[3]

Thomas V. Colby, M.D.[4]

Masato Kono, M.D, Ph.D.[1]

Dai Hashimoto, M.D., Ph.D.[1]

Noriyuki Enomoto, M.D., Ph.D.[1]

Tomoyuki Fujisawa, M.D., Ph.D.[1]

Naoki Inui, M.D., Ph.D.[1]

Takafumi Suda, M.D., Ph.D.[1]

Kingo Chida, M.D., Ph.D.[1]

Affiliations:

[1]Second division, Department of Internal Medicine, Hamamatsu University School of

1

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

[2]Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public

School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

[3]Diagnostic and Interventional Radiology, Osaka University Graduate School of

Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

[4]Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East

Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

2

Word count paper: 2779

Word count abstract: 292

ABSTRACT

Background   Acute exacerbation (AE) in idiopathic pulmonary fibrosis is

characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially

rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives   To investigate the risk factors and prognosis associated with AE in

patients with RA-ILD.

Design   A retrospective cohort study.

Setting   A single academic hospital.

Participants   51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology

for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function

tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures   Overall survival and cumulative AE incidence were

analysed using Kaplan–Meier method. Cox hazards analysis was used to determine

significant variables associated with AE occurrence and survival status.

Results   A total of 11 patients (22%) developed AE, with an overall 1-year incidence

of 2.8%. Univariate analysis revealed that higher age at ILD diagnosis [hazard ratio

4

(HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial

pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and

treatment with methotrexate (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were risk factors

for AE. Of 11 patients who developed AE during observation period, seven (64%) died

of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95%

CI, 1.39–4.56; $P = 0.003$).

Conclusions   In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on

HRCT and treatment with methotrexate are risk factors for AE. Furthermore, AE has a

serious impact on their survival. We should carefully observe the patients having any of

these risk factors.

5

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis (IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with RA-ILD?

Key messages;

In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on HRCT, and treatment with methotrexate are risk factors for AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE may have a serious impact on the survival of patients with RA-ILD as well as that with IPF. Thus, the patients with any of these risk factors should be carefully observed.

Given its retrospective study design, it is subject to several possible biases. Therefore, prospective studies are necessary to confirm our results.

6

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterized by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, and an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is the most common extra-articular manifestations,[6] with a prevalence of 1%–58%.[7-12] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated with AE in patients

7

with RA-ILD are not clarified.

In the present study, we attempted to elucidate the cumulative incidence of AE, its risk factors, and prognostic factors in patients with RA-ILD.

MATERIALS AND METHODS

Subjects

Institutional review board in Hamamatsu University School of Medicine approved this study (approval number 24-191) and waived patient approval or informed consent because the study involved a retrospective review of patient records and images. We retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA.[13] Patients with other coexisting CVD were excluded. In addition, because our aim was to investigate the features of AE among patients with a chronic course of RA-ILD, patients with no evidence of chronic ILD were also excluded.

ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings. HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities

8

and honeycomb patterns were interpreted and defined as ILD by a consensus between radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to definitively diagnose ILD or rule out other diseases. The patients with environmental exposures, suspected of drug induced pneumonia (ILD developed within 1 year after initiation of new drug), or with other known causes of ILD were excluded after considering exposure history and the findings of appropriate tests and histopathological examinations.

Acute exacerbation (AE)

AE was defined using recently proposed criteria[1] that were slightly modified for adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or development of dyspnea within 30 days of onset, new bilateral ground-glass abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern on HRCT, no evidence of pulmonary infection on negative respiratory culture, including endotracheal aspirate or bronchoalveolar lavage, and serological test results for respiratory pathogens, and exclusion of alternative causes such as left heart failure, pulmonary embolism, and an identifiable cause of acute lung injury. Patients with AE

were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,

and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,

fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if

necessary, CT scanning with intravenous contrast were performed to rule out left heart

failure or pulmonary thromboembolism. The patients who developed acute pneumonitis

within 1 year after initiation of drug for RA were excluded because drug-induced

pneumonitis was not completely ruled out. Patients who did or did not develop AE

during the observation period were classified into the AE and non-AE groups,

respectively.

Data collection

All clinical and laboratory data were collected from medical records. The observation

period was calculated from the date of diagnosis of RA-ILD to the last visit. The

AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis

and the first AE occurrence (AE group) or the last visit (non-AE group).

Review of radiographic findings

HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images

10

comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were

reconstructed by a high spatial frequency algorithm, and were displayed at window

settings appropriate for viewing the lung parenchyma (window level, -600 to -800

Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were

randomised and reviewed independently by two expert chest radiologists (with 23 and

12 years of experience) who were unaware of the related clinical information.

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a

non-UIP pattern according to recent guideline.[14] Briefly, a UIP pattern on HRCT was

characterised by subpleural and basal predominance, reticular abnormalities,

honeycombing with or without traction bronchiectasis and the absence of features listed

as inconsistent with a UIP pattern, including upper or mid-lung predominance,

peribronchovascular predominance, extensive ground glass abnormalities, profuse

micronodules, discrete cysts, diffuse mosaic attenuation/air-trapping and consolidation

in bronchopulmonary segment(s)/lobe(s). If the HRCT pattern did not meet the criteria,

it was interpreted as a non-UIP pattern. Disagreements regarding HRCT interpretation

were resolved by a consensus between both radiologists.

Review of histopathological findings

11

SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was

originally made in all cases on the basis of histological features evaluated by a lung

pathologist at our hospital, correlated with the clinical and radiological findings. All

SLB specimens were also reviewed by a second lung pathologist with 36 years of

experience. The histological classification of interstitial pneumonia was based on the

consensus statement criteria for idiopathic interstitial pneumonias,[15] and histological

patterns that could not be classified according to the criteria were categorised as

unclassified interstitial pneumonia.

Statistical analysis

All values are expressed as median (range) or number (%). The Mann-Whitney U test

was used for nonparametric comparisons involving continuous data, whereas Fisher's

exact test was used for comparing categorical data. Interobserver agreement on HRCT

pattern was analyzed using the κ statistic test. Interobserver agreement was classified as

follows: poor (κ = 0–0.20), fair (κ = 0.21–0.40), moderate (κ = 0.41–0.60), good (κ =

0.61–0.80) and excellent (κ = 0.81-1.00). Survival was evaluated using the

Kaplan–Meier method and the log-rank test. The cumulative AE incidence was obtained

from a Kaplan–Meier survival curve by treating AE as the death variable. The 1-year

AE incidence was calculated by dividing the number of patients who developed AE by

the total of AE-free period (year) of all the patients. Cox hazards analysis was used to

determine significant variables associated with survival and AE occurrence. In all

analyses, $P < 0.05$ was considered statistically significant. All data were analysed using

commercially available software (JMP version 9.0.3a, SAS Institute Inc, Cary, NC,

USA).

RESULTS

Patient characteristics (Table 1)

The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)

years and 62 (range, 31–83) years, respectively. The median observation period and

AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.

During the observation period, 11 patients (22%) developed AE. The median age at

the onset of AE was 72 (range, 60–86) years. There were no statistically significant

differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,

AE-free period, smoking habits, predicted forced vital capacity (%FVC) and arterial

oxygen pressure (PaO$_2$) between the AE and non-AE groups.

In the AE group, seven of 11 patients (64%) died of initial AE during the observation

13

period. In the non-AE group, 5 of 40 patients (13%) died. There was a statistically

significant difference in the mortality rate between the AE and non-AE groups.

HRCT pattern (Table 1)

Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.

HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)

patients in the AE group demonstrated a UIP pattern. Interobserver agreement between

both radiologists was moderate (κ statistic test, $\kappa = 0.44$). The number of patients who

exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the

non-AE group.

Correlation between histopathological findings and HRCT pattern (Table 2)

Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis

revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and

an unclassified interstitial pneumonia in 1. The correlation between histopathological

and HRCT pattern was evaluated in 21 histopathologically confirmed patients. When

the pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive

predictive value and negative predictive value for detecting histopathological UIP was

14

41.7%, 100%, 100% and 56.3%, respectively.

Treatment for RA (Table 3)

Of the 51 patients, 37 (73%) had received treatment for RA at their final visit

(non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) received

corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10 (20%)

received MTX and 17 (33%) received other drugs. The number of patients who received

MTX was significantly higher in the AE group than in the non-AE group (55% vs. 10%,

$P = 0.001$).

AE incidence

The cumulative AE incidence in patients with RA-ILD is shown in Figure 1. The AE

incidence was significantly higher in patients with a UIP pattern on HRCT (UIP pattern

group) than in patients with a non-UIP pattern on HRCT (non-UIP pattern group)

(log-rank test, $P = 0.018$). The overall 1-year AE incidence was 2.8%. The 1-year AE

incidence was 6.5% in the UIP pattern group and 1.7 % in the non-UIP pattern group.

Univariate analysis (Table 4) revealed that higher age at ILD diagnosis [hazard ratio

(HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], UIP pattern on HRCT

15

(HR, 1.95; 95% CI, 1.07–3.63; P = 0.03) and treatment with MTX (HR, 3.04; 95% CI, 1.62–6.02; P = 0.001) were significant risk factors for AE occurrence.

Survival

The overall survival of patients with RA-ILD is shown in Figure 2. The 5-year survival was 90% in all patients, 70% in the UIP pattern group and 97% in the non-UIP pattern group. Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern group (log-rank test, P = 0.04). In addition, significantly worse survival was demonstrated in the AE group compared with the non-AE group (Figure 3, log-rank test, P = 0.001).

Univariate analysis (Table 5) revealed that higher age at ILD diagnosis (HR, 1.08; 95% CI, 0.99–1.17; P = 0.057) and UIP pattern on HRCT (HR, 1.74; 95% CI, 0.97–3.12; P = 0.06) showed a trend toward poor outcome, while AE (HR, 2.47; 95% CI, 1.39–4.56; P = 0.003) was significantly associated with poor survival.

DISCUSSION

To our knowledge, the present study is the first one focusing on the risk factors and prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence

16

was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern

on HRCT, MTX treatment and higher age at ILD diagnosis were significant risk factors

for AE. Furthermore, AE was a prognostic factor for poor survival.

The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[16,

17] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 %

for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, patients with RA-ILD

had a relatively lower incidence of AE. However, the 1-year AE incidence among

patients with a UIP pattern on HRCT was 6.5%, comparable to that in patients with IPF.

Furthermore, a UIP pattern on HRCT was a risk factor for AE. In a previous report of

small number of biopsy-proven cases, AE incidence among patients with RA-UIP was

11.1%, also similar to that among patients with IPF.[4] The correlation between

pathological and radiological UIP patterns has been established in IPF, but not in

RA-ILD.[18] In the present study, determination of a UIP pattern on HRCT exhibited

high specificity and positive predictive values for the detection of pathological UIP.

Therefore, a typical UIP pattern on HRCT was assumed to be highly suggestive of

pathological UIP in patients with RA-ILD as well as IPF.[14, 18] Collectively, these

results suggest that AE occurs less frequently in RA-ILD than in IPF, while AE

incidence in a subgroup with pathological UIP or a UIP pattern on HRCT may be as

17

high as that in patients with IPF.

The present study also identified MTX treatment as a risk factor for AE. MTX is

widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic

criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed

previously.[19] However, the specificity of the criteria has not been fully examined yet.

MTX-pneumonitis typically occurs with acute/subacute onset early in the course of

MTX treatment,[19-22] in particular, mostly within the first year[23] and often presents

a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis generally

respond to discontinuation of MTX or corticosteroid treatment and have a favorable

prognosis.[19-22] In the present study, 6 of 11 patients with AE had received MTX, and

5 of the 6 patients had been treated for 3 or more years. The remaining patient had been

treated for 1 year. In all 6 patients, their respiratory conditions progressively

deteriorated despite discontinuation of MTX, and they poorly responded to high-dose

corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment

duration and clinical features, we diagnosed these patients with AE of RA-ILD. Similar

to AE in patients with IPF, the etiology of AE in RA-ILD is unknown; however, several

reports have suggested that AE may be a distinct manifestation of the primary disease

process, a distinct condition associated with undiagnosed infection, or a subsequent

acceleration of a fibroproliferative process caused by acute direct stress to the lung.[1]

In the present study, RA joint disease activity in all patients with AE was stable at the

time of AE occurrence; therefore, RA activity may not be related to AE occurrence, a

finding similar to that of a previous study.[4] MTX possibly accelerates the

fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk

factor for RA-ILD progression.[10] For RA-ILD, MTX may be associated not only with

newly developing drug-induced pneumonitis but also with deterioration of pre-existing

ILD, including AE. Therefore, we think that MTX treatment should be avoided in RA

patients with ILD.

The present study found that patients with a UIP pattern on HRCT had significantly

poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic

factor for poor outcome. AE has a serious impact on the survival of patients with

IPF,[17] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these

reports, the present study revealed that seven (64%) of 11 patients with AE died of

respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE

group was significantly poorer than that in the non-AE group. Therefore, AE is

suggested to be a predictor of poor prognosis in patients with RA-ILD as well as

patients with IPF.

19

Other prognostic factors in RA-ILD have been reported, including pathological UIP,[24-28] UIP pattern on HRCT,[29] and age at RA-ILD onset.[30] In the present study, pathological UIP could not be identified as prognostic factors because the number of biopsy-proven cases were small. However, we observed similar results regarding UIP pattern on HRCT and age at RA-ILD onset.

This study had several limitations. First, given its retrospective study design, it is subject to several possible biases. For instance, selection and recall bias may exist. Second, because of the relatively small sample size, it may be difficult to determine the precise incidence of AE. Therefore, larger studies are necessary to confirm our results. Third, because the presence of a UIP pattern on HRCT had low sensitivity for the detection of pathologic UIP, it was likely that some patients with a non-UIP pattern on HRCT may have had pathological UIP. Finally, RA includes a variety of manifestations. Therefore, other comorbidities may have affected the results.

In conclusion, higher age at ILD diagnosis, UIP pattern on HRCT and treatment with MTX are risk factors for AE occurrence in patients with RA-ILD. Furthermore, the mortality associated with AE is high and AE is prognostic factor for poor outcome. AE has a serious impact on the survival of patients with RA-ILD. Thus, we should carefully observe the patients having any of these risk factors.

20

ACKNOWLEDGMENT

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S., and K.C. revised the paper.

All authors approved the paper.

Competing interest:

All authors do not have any personal or financial support or involvement with

organization(s) that have financial interest in the subject matter, or any competing

interest.

Funding:

This research received no specific grant from any funding agency in the public,

commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this

study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images.

Copyright:

I *[Yutaro Nakamura]* the Corresponding Author of this article contained within the

original manuscript which includes any diagrams & photographs, other illustrative

material, video, film or any other material howsoever submitted by the Contributor(s) at

22

any time and related to the Contribution ("the Contribution") have the right to grant on

behalf of all authors and do grant on behalf of all authors, a licence to the BMJ

Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be

published in BMJ Open and any other BMJ Group products and to exploit all subsidiary

rights, as set out in the licence

Data sharing:

No unpublished data from the study are available.

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical
    Research Network Investigators. Acute exacerbations of idiopathic pulmonary
    fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.

2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung
    disease. *Histopathology.* 2011;58:525-30.

3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia
    associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.

4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other
    than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.

5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.

6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.*
    1998;19:667-85.

7. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain:
    occurrence of extra-articular manifestations and estimates of disease severity. *Ann
    Rheum Dis.* 2003;62:897–900.

8. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with
    rheumatoid arthritis as assessed by high resolution computed tomography, chest

24

radiography, and pulmonary function tests. *Thorax.* 2001;56:622–7.

9. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. *Am J Respir Crit Care Med.* 1997;156:528–35.

10. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. *Arch Intern Med.* 2008;168:159–66.

11. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. *J Rheumatol.* 2008;35:1513–21.

12. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722–7.

13. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988;31:315-24.

14. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011;183:788-824.

25

15. American Thoracic Society/European Respiratory Society International

Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.

Am J Respir Crit Care Med. 2002;165:277-304.

16. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary

fibrosis. *Chest.* 2007;132:1652-8.

17. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary

fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.

18. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung

disease: the relevance of histopathologic and radiographic pattern. *Chest.*

2009;136:1397-405.

19. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,

and histopathologic features of methotrexate-associated lung injury in patients with

rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.*

1997;40:1829-37.

20. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced

lung injury in patients with rheumatoid arthritis. A multicenter, case-control study.

Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.

26

21. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.* 2009;68:1100-4.

22. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. *Eur Respir J.* 2000;15:373-81.

23. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.

24. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.

25. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am Rev Respir Dis.* 1985;131:770-7.

26. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.

27. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.

28. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care*

Med. 2007;175:705-11.

29. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in

rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.*

2010;35:1322-8.

30. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study).

Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an

inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.

Table 1 Clinical characteristics

Characteristics	Total	Non-AE group[#]	AE group[¶]	P value[+]
	N = 51 (100)	N = 40 (78)	N = 11 (22)	
Median age, years (range)				
at RA diagnosis	61 (28-82)	60 (28-81)	65 (42-82)	0.15
at ILD diagnosis	62 (31-83)	62 (31-83)	69 (58-83)	0.15
at AE onset			72 (60-86)	
Sex Male, n (%)	29 (57)	23 (58)	6 (55)	0.86
Observation period, years (range)	8.5 (1-17)	9 (1-17)	6.4 (2-14)	0.45
AE-free period, years (range)	7(1-17)	9 (1-17)	6 (2-14)	0.19
Smoking habit, n (%)				
Never	20 (39)	18 (45)	2 (18)	
Former	24 (47)	16 (40)	8 (73)	0.15
Current	7 (14)	6 (15)	1 (9)	
PaO_2, torr (range)	82.4 (67-109)	81 (67-102)	85.8 (74-109)	0.19
%FVC, % (range)	91.1 (50.6-130)	87.5 (51-130)	95 (60-125)	0.38
HRCT pattern, n (%)				
UIP pattern	14 (27)	8 (20)	6 (55)	0.02[§]
non-UIP pattern	37 (73)	32 (80)	5 (45)	
Death during observation period, n (%)	12 (24)	5 (13)	7 (64)	0.001[§]
caused by respiratory failure	8 (16)	2 (5)	7 (64)	0.02[§]
caused by other diseases	4 (8)	3 (8)	0 (0)	

Data are presented as n (%), median (range).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶] AE group, patients who developed AE during observation period.

[+] Non-AE group vs AE group

[§] $p < 0.05$

In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding and 2 of unknown causes.

29

Table 2 Correlation between histopathological findings and HRCT pattern in 21 histopathologically confirmed patients.

	Histopathological pattern		Total
	UIP	Other pattern	
UIP pattern on HRCT	5	0	5
non-UIP pattern on HRCT	7	9	16
Total	12	9	21

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

30

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

	Total	non-AE group[+]	AE group[§]	P value
	N = 51	N = 40 (78%)	N = 11 (22%)	
Treatment, yes	37 (73)	27(68)	10 (91)	0.12
Corticosteroid	29 (57)	22 (55)	7 (64)	0.61
Immunosuppressant except for MTX	17 (33)	14 (35)	3 (27)	0.63
MTX	10 (20)	4 (10)	6 (55)	0.001[*]
Other drugs	17 (33)	13 (33)	4 (36)	0.81

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cycrophosphaminde (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

[+] Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

[*] $p < 0.05$

31

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	1.03	0.97-1.10	0.35
Age at ILD diagnosis	1.11	1.02-1.21	0.01[+]
Sex, male	0.90	0.49-1.69	0.73
Smoking habit, yes	1.60	0.81-4.10	0.19
UIP pattern on HRCT, yes	1.95	1.07-3.63	0.03[+]
PaO_2 at ILD diagnosis	1.05	0.98-1.12	0.14
%FVC at ILD diagnosis	1.02	0.99-1.06	0.24
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	0.97	0.53-1.92	0.94
Immunosuppressant except for MTX	0.76	0.35-1.41	0.39
MTX	3.04	1.62-6.02	0.001[+]
Other drugs	0.98	0.50-1.80	0.96

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

32

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	0.98	0.93-1.04	0.48
Age at ILD diagnosis	1.08	0.99-1.17	0.057
Sex, male	1.14	0.63-2.22	0.67
Smoking habit, yes	1.70	0.87-4.35	0.13
UIP pattern on HRCT, yes	1.74	0.97-3.12	0.06
PaO_2 at ILD diagnosis	1.05	0.98-1.11	0.15
%FVC at ILD diagnosis	1.01	0.98-1.04	0.55
AE during observation period, yes	2.47	1.39-4.56	0.003[+]
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	1.23	0.67-2.65	0.52
Immunosuppressant except for MTX	0.69	0.32-1.27	0.25
MTX	1.44	0.67-2.68	0.31
Other drugs	0.76	0.36-1.41	0.40

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

33

Figure legends

Figure 1. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE

compared with non-UIP pattern on HRCT (log-rank p=0.018).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP,

usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 2. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with

those with non-UIP pattern on HRCT (log-rank p=0.04).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly

worse survival compared with those who did not (non-AE group) (log-rank p=0.001).

AE, acute exacerbation.

34

FIGURE 1.

Figure 1. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank p=0.018).
AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
85x85mm (300 x 300 DPI)

FIGURE 2.

Figure 2. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank p=0.04).
UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
85x85mm (300 x 300 DPI)

FIGURE 3.

Figure 3. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly worse survival compared with those who did not (non-AE group) (log-rank p=0.001).
AE, acute exacerbation.
85x85mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported
Objectives	3	State specific objectives, including any prespecified hypotheses
Methods		
Study design	4	Present key elements of study design early in the paper
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up
		(*b*) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias	9	Describe any efforts to address potential sources of bias
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding
		(*b*) Describe any methods used to examine subgroups and interactions
		(*c*) Explain how missing data were addressed
		(*d*) If applicable, explain how loss to follow-up was addressed
		(*e*) Describe any sensitivity analyses
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		(c) Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included
		(*b*) Report category boundaries when continuous variables were categorized
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period

Other analyses	(17)	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses
Discussion		
Key results	(18)	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation	(20)	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability	(21)	Discuss the generalisability (external validity) of the study results
Other information		
Funding	(22)	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.

BMJ open

Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

SCHOLARONE™
Manuscripts

Title: Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

Authors:

Hironao Hozumi, M.D., Ph.D.[1]

Yutaro Nakamura, M.D., Ph.D.[1]

Takeshi Johkoh, M.D., Ph.D.[2]

Hiromitsu Sumikawa, M.D., Ph.D.[3]

Thomas V. Colby, M.D.[4]

Masato Kono, M.D, Ph.D.[1]

Dai Hashimoto, M.D., Ph.D.[1]

Noriyuki Enomoto, M.D., Ph.D.[1]

Tomoyuki Fujisawa, M.D., Ph.D.[1]

Naoki Inui, M.D., Ph.D.[1]

Takafumi Suda, M.D., Ph.D.[1]

Kingo Chida, M.D., Ph.D.[1]

Affiliations:

[1]Second division, Department of Internal Medicine, Hamamatsu University School of

1

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

[2]Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public

School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

[3]Diagnostic and Interventional Radiology, Osaka University Graduate School of

Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

[4]Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East

Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

2

Word count paper: 3382

Word count abstract: 280

3

ABSTRACT

Background   Acute exacerbation (AE) in idiopathic pulmonary fibrosis is

characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially

rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives   To investigate the risk factors and prognosis associated with AE in

patients with RA-ILD.

Design   A retrospective case-control study.

Setting   A single academic hospital.

Participants   51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology

for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function

tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures   Overall survival and cumulative AE incidence were

analysed using Kaplan–Meier method. Cox hazards analysis was used to determine

significant variables associated with AE occurrence and survival status.

Results   A total of 11 patients (22%) developed AE, with an overall 1-year incidence

of 2.8%. Univariate analysis revealed that higher age at ILD diagnosis [hazard ratio

4

(HR), 1.11; 95% confidence interval (CI), 1.02–1.21; *P* = 0.01], usual interstitial

pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; *P* = 0.03) and

treatment with methotrexate (HR, 3.04; 95% CI, 1.62–6.02; *P* = 0.001) were risk factors

for AE. Of 11 patients who developed AE during observation period, seven (64%) died

of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95%

CI, 1.39–4.56; *P* = 0.003).

Conclusions   In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on

HRCT and treatment with methotrexate are risk factors for AE. Furthermore, AE has a

serious impact on their survival.

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis

(IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease

(RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with

RA-ILD?

Key messages;

In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on HRCT, and

treatment with methotrexate are risk factors for AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE has a serious impact on the survival of patients with RA-ILD.

Given its retrospective study design, it is subject to several possible biases. Therefore,

prospective studies are necessary to confirm our results.

6

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, and an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is one of common extra-articular manifestations.[6, 7] The reported prevalence is variable (1–58%) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common

7

CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated

with AE in patients with RA-ILD are not clarified.

In the present study, we attempted to elucidate the cumulative incidence of AE, its

risk factors, and prognostic factors in patients with RA-ILD.

MATERIALS AND METHODS

Subjects

Institutional review board in Hamamatsu University School of Medicine approved

this study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images. We

retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995

and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the

diagnostic criteria of the American College of Rheumatology for RA.[14] Patients with

other coexisting CVD were excluded. In addition, because our aim was to investigate

the features of AE among patients with a chronic course of RA-ILD, patients with no

evidence of chronic ILD were also excluded.

ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,

high resolution computed tomography (HRCT) findings, and lung biopsy findings.

8

HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities and honeycomb patterns were interpreted and defined as ILD by a consensus between radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to definitively diagnose ILD or rule out other diseases. The patients with environmental exposures, suspected of drug induced pneumonia (ILD developed within 1 year after initiation of new drug), or with other known causes of ILD were excluded after considering exposure history and the findings of appropriate tests and histopathological examinations.

Acute exacerbation (AE)

AE was defined using recently proposed criteria[1] that were slightly modified for adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or development of dyspnea within 30 days of onset, new bilateral ground-glass abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern on HRCT, no evidence of pulmonary infection on negative respiratory culture, including endotracheal aspirate or bronchoalveolar lavage, and serological test results for respiratory pathogens, and exclusion of alternative causes such as left heart failure,

9

pulmonary embolism, and an identifiable cause of acute lung injury. Patients with AE

were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,

and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,

fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if

necessary, CT scanning with intravenous contrast were performed to rule out left heart

failure or pulmonary thromboembolism. The patients who developed acute pneumonitis

within 1 year after initiation of drug for RA were excluded because drug-induced

pneumonitis was not completely ruled out. Patients who did or did not develop AE

during the observation period were classified into the AE and non-AE groups,

respectively.

Data collection

All clinical and laboratory data were collected from medical records. The observation

period was calculated from the date of diagnosis of RA-ILD to the last visit. The

AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis

and the first AE occurrence (AE group) or the last visit (non-AE group).

Review of radiographic findings

10

HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images

comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were

reconstructed by a high spatial frequency algorithm, and were displayed at window

settings appropriate for viewing the lung parenchyma (window level, -600 to -800

Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were

randomised and reviewed independently by two expert chest radiologists (with 23 and

12 years of experience) who were unaware of the related clinical information.

Interobserver agreement was classified as follows: poor (κ = 0–0.20), fair (κ =

0.21–0.40), moderate (κ = 0.41–0.60), good (κ = 0.61–0.80) and excellent (κ =

0.81-1.00).

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a

non-UIP pattern according to recent guideline with slight modification.[15] Briefly, a

UIP pattern on HRCT was characterised by subpleural and basal predominance,

reticular abnormalities, honeycombing with or without traction bronchiectasis and the

absence of features listed as inconsistent with a UIP pattern, including upper or

mid-lung predominance, peribronchovascular predominance, extensive ground glass

abnormalities, profuse micronodules, discrete cysts, diffuse mosaic

attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If

11

the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.

Disagreements regarding HRCT interpretation were resolved by a consensus between

both radiologists.

Review of histopathological findings

SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was

originally made in all cases on the basis of histological features evaluated by a lung

pathologist at our hospital, correlated with the clinical and radiological findings. All

SLB specimens were also reviewed by a second lung pathologist with 36 years of

experience. The histological classification of interstitial pneumonia was based on the

consensus statement criteria for idiopathic interstitial pneumonias,[16] and histological

patterns that could not be classified according to the criteria were categorised as

unclassified interstitial pneumonia.

Statistical analysis

All values are expressed as median (range) or number (%). The Mann-Whitney U test

was used for nonparametric comparisons involving continuous data, whereas Fisher's

exact test was used for comparing categorical data. Interobserver agreement on HRCT

pattern was analyzed using the κ statistic test. Survival was evaluated using the

Kaplan–Meier method and the log-rank test according to observation period. The

cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating

AE as the death variable according to AE free period. The 1-year AE incidence was

based on person year method and calculated by dividing the number of patients who

developed AE by the total of AE-free period (year) of all the patients. Cox hazards

analysis was used to determine significant variables associated with survival and AE

occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data

were analysed using commercially available software (JMP version 9.0.3a, SAS

Institute Inc, Cary, NC, USA).

RESULTS

Patient characteristics (Table 1)

A total of 82 patients with RA-ILD were identified from medical records at

Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8

with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3

suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom

no initial HRCT images were available for review were also excluded. The remaining

51 patients with RA-ILD were included in this study.(Figure 1)

The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)

years and 62 (range, 31–83) years, respectively. The median observation period and

AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.

During the observation period, 11 patients (22%) developed AE. The median age at

the onset of AE was 72 (range, 60–86) years. There were no statistically significant

differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,

AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of

RA-ILD, and arterial oxygen pressure (PaO$_2$) at diagnosis of RA-ILD between the AE

and non-AE groups. Also there were no statistically significant differences in articular

disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE

occurrence (AE group).

In the AE group, seven of 11 patients (64%) died of initial AE during the observation

period. In the non-AE group, 2 of 40 patients (5%) died of respiratory failure. There was

a statistically significant difference in the mortality rate between the AE and non-AE

groups.

Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51

patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in

14

2, glomerulonephritis in 1, rheumatoid nodule in 2). There was no significant difference

in the incidence between AE group and non-AE group (27% vs. 13%, *P*=0.26).

HRCT pattern (Table 1)

Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.

HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)

patients in the AE group demonstrated a UIP pattern. Interobserver agreement between

both radiologists was moderate (κ statistic test, κ = 0.44). The number of patients who

exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the

non-AE group.

When HRCT pattern was identified as a UIP pattern, the positive predictive value and

negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

Diagnostic accuracy of HRCT pattern for histopathological pattern (Table 2)

Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis

revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and

an unclassified interstitial pneumonia in 1. The diagnostic accuracy of HRCT pattern for

histopathological pattern was evaluated in 21 histopathologically confirmed patients.

15

When the pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity,

positive predictive value and negative predictive value for detecting histopathological

UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Treatment for RA (Table 3)

Of the 51 patients, 37 (73%) had received treatment for RA at their final visit

(non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had

received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10

(20%) received MTX and 17 (33%) received other drugs. There were 6 (55%) patients

who had received MTX in AE group while 4 (10%) patients in non-AE group and

statistically significant difference was observed between the groups ($P = 0.001$).

No patients had received MTX before in AE group while 2 in non-AE group. Thus,

there were 6 (55%) patients who had experienced MTX treatment during observation

period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX

dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE

group and 802mg (32-2496) in 6 patients among non-AE group. No statistically

significant difference was observed between two groups in cumulative MTX dose

(P=0.20).

16

Articular disease activities (RF and DAS28-CRP) were compared between patients

who had received MTX at the last visit or at the first AE occurrence, and those who had

not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) (P=0.25),

Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) (P=0.78),

respectively. There were no statistically significant differences in articular disease

activities.

AE incidence

The cumulative AE incidence in patients with RA-ILD is shown in Figure 2. The

5-year AE incidence was 11% [95% confidence interval (CI), 2–21%] in all patients,

33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT (UIP pattern group) and

3% (95% CI, 0–9%) in patients with a non-UIP pattern on HRCT (non-UIP pattern

group). The AE incidence was significantly higher in UIP pattern group than in

non-UIP pattern group (log-rank test, $P = 0.018$). The overall 1-year AE incidence was

2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the

non-UIP pattern group.

Univariate analysis (Table 4) revealed that higher age at ILD diagnosis [hazard ratio

(HR), 1.11; 95% CI, 1.02–1.21; $P = 0.01$], UIP pattern on HRCT (HR, 1.95; 95% CI,

17

1.07–3.63; P = 0.03) and treatment with MTX (HR, 3.04; 95% CI, 1.62–6.02; P =

0.001) were significant risk factors for AE occurrence.

Survival

The overall survival of patients with RA-ILD is shown in Figure 3.

The 5-year survival was 90% (95% CI, 81–98%) in all patients, 70% (95% CI, 44–94%)

in the UIP pattern group and 97% (95% CI, 92–100%) in the non-UIP pattern group.

Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern

group (log-rank test, P = 0.04). In addition, significantly worse survival was

demonstrated in the AE group compared with the non-AE group (Figure 4, log-rank test,

P = 0.001).

Univariate analysis (Table 5) revealed that higher age at ILD diagnosis (HR, 1.08;

95% CI, 0.99–1.17; P = 0.057) and UIP pattern on HRCT (HR, 1.74; 95% CI,

0.97–3.12; P = 0.06) showed a trend toward poor outcome, while AE (HR, 2.47; 95%

CI, 1.39–4.56; P = 0.003) was significantly associated with poor survival.

DISCUSSION

To our knowledge, the present study is the first one focusing on the risk factors and

18

prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence

was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern

on HRCT, MTX treatment and higher age at ILD diagnosis were significant risk factors

for AE. Furthermore, AE was a prognostic factor for poor survival.

The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[17,

18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 %

for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, the 1-year AE incidence

among patients with a UIP pattern on HRCT was 6.5% and cumulative incidence was

significantly higher in UIP pattern group than in non-UIP pattern group. Furthermore, a

UIP pattern on HRCT was a risk factor for AE. In a previous report of small number of

biopsy-proven cases, AE incidence among patients with RA-UIP was reported to be

11.1%, similar to that among patients with IPF.[4] The correlation between pathological

and radiological UIP patterns has been established in IPF, but not in RA-ILD.[19] In the

present study, determination of a UIP pattern on HRCT exhibited high specificity and

positive predictive values for the detection of pathological UIP pattern. Therefore, a

typical UIP pattern on HRCT was assumed to be highly suggestive of pathological UIP

pattern in patients with RA-ILD as well as IPF.[15, 19] Collectively, these results

suggest that AE incidence in a subgroup with pathological UIP pattern or a UIP pattern

19

on HRCT may be higher than that in other patterns..

The present study also identified MTX treatment as a risk factor for AE. MTX is widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed previously.[20] However, the specificity of the criteria has not been fully examined yet. MTX-pneumonitis typically occurs with acute/subacute onset early in the course of MTX treatment,[20-23] in particular, mostly within the first year[24] and often presents a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis generally respond to discontinuation of MTX or corticosteroid treatment and have a favorable prognosis.[20-23] In the present study, 6 of 11 patients with AE had received MTX, and 5 of the 6 patients had been treated for 3 or more years. The remaining patient had been treated for 1 year. In all 6 patients, their respiratory conditions progressively deteriorated despite discontinuation of MTX, and they poorly responded to high-dose corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment duration and clinical features, we diagnosed these patients with AE of RA-ILD.

Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown; however, several reports have suggested that AE may be a distinct manifestation of the primary disease process, a distinct condition associated with undiagnosed infection, or a

20

subsequent acceleration of a fibroproliferative process caused by acute direct stress to the lung.[1] In the present study, DAS28-CRP in all patients with AE showed low disease activity or remission at the time of AE occurrence, and no significant difference in articular disease activities was observed between AE group and non-AE group or regardless of MTX treatment; therefore, RA activity may not be related to AE occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates the fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk factor for RA-ILD progression.[12] For RA-ILD, MTX may be associated not only with newly developing drug-induced pneumonitis but also with deterioration of pre-existing ILD, including AE.

The present study found that patients with a UIP pattern on HRCT had significantly poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic factor for poor outcome. AE has a serious impact on the survival of patients with IPF,[18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these reports, the present study revealed that seven (64%) of 11 patients with AE died of respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE group was significantly poorer than that in the non-AE group. Therefore, AE is suggested to be a predictor of poor prognosis in patients with RA-ILD as well as

patients with IPF.

Other prognostic factors in RA-ILD have been reported, including pathological

UIP,[25-29] UIP pattern on HRCT,[30] and age at RA-ILD onset.[31] In the present

study, pathological UIP could not be identified as prognostic factors because the number

of biopsy-proven cases were small. However, we observed similar results regarding UIP

pattern on HRCT and age at RA-ILD onset.

In our study, the average time between age at onset of RA and that of RA-ILD was

relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported

that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In

another point of view, since the current authors' institution is regional referral center for

interstitial lung disease, referral bias might have increased the proportion of patients

with early-stage ILD, leading above results.

This study had several limitations. First, given its retrospective study design, it is

subject to several possible biases. For instance, selection and recall bias may exist.

Second, because of the relatively small sample size, it may be difficult to determine the

precise incidence of AE and the number of event (AE occurrence or death) was too

small to perform multivariate analysis. Therefore, larger studies are necessary to

confirm our results. Third, because the presence of a UIP pattern on HRCT had low

sensitivity and negative predictive value for the detection of pathologic UIP, it was

likely that some patients with a non-UIP pattern on HRCT may have had pathological

UIP. HRCT criteria used in our study do not aim to detect pathological UIP but to

clinically diagnose IPF and to exclude alternative diagnosis.[15] The frequency of

honeycombing on HRCT differs between RA-ILD and IPF, and some ILDs by other

causes including RA-ILD have some of findings inconsistent with UIP. Therefore,

HRCT pattern in RA-ILD may be more frequently interpreted as non-UIP pattern than

that in IPF. In our study, 2 of 5 patients with histopathological UIP in the absence of a

UIP pattern on HRCT develop AE. Thus, SLB may have to be considered for these

patients to make pathological diagnosis and to predict AE. Finally, RA includes a

variety of manifestations. Therefore, other comorbidities may have affected the results.

In conclusion, higher age at ILD diagnosis, UIP pattern on HRCT and treatment with

MTX are risk factors for AE occurrence in patients with RA-ILD. Furthermore, the

mortality associated with AE is high and AE is prognostic factor for poor outcome.

Larger prospective studies investigating acute exacerbations in RA-ILD are indicated.

ACKNOWLEDGMENT

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the

integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed

acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and

analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S.,

and K.C. revised the paper.

All authors approved the paper.

24

Competing interest:

All authors do not have any personal or financial support or involvement with

organization(s) that have financial interest in the subject matter, or any competing

interest.

Funding:

This research received no specific grant from any funding agency in the public,

commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this

study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images.

Copyright:

I [*Yutaro Nakamura*] the Corresponding Author of this article contained within the

original manuscript which includes any diagrams & photographs, other illustrative

material, video, film or any other material howsoever submitted by the Contributor(s) at

25

any time and related to the Contribution ("the Contribution") have the right to grant on

behalf of all authors and do grant on behalf of all authors, a licence to the BMJ

Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be

published in BMJ Open and any other BMJ Group products and to exploit all subsidiary

rights, as set out in the licence

26

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.

2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.

3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.

4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.

5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.

6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.

7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722–7.

8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

27

their impact on outcome. Rheumatology (Oxford). 2013;52:99-110.

9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. *Ann Rheum Dis.* 2003;62:897–900.

10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. *Thorax.* 2001;56:622–7.

11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. *Am J Respir Crit Care Med.* 1997;156:528–35.

12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. *Arch Intern Med.* 2008;168:159–66.

13. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. *J Rheumatol.* 2008;35:1513–21.

14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988;31:315-24.

28

15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on

    Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:

    idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and

    management. *Am J Respir Crit Care Med.* 2011;183:788-824.

16. American Thoracic Society/European Respiratory Society International

    Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.

    Am J Respir Crit Care Med. 2002;165:277-304.

17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary

    fibrosis. *Chest.* 2007;132:1652-8.

18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary

    fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.

19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung

    disease: the relevance of histopathologic and radiographic pattern. *Chest.*

    2009;136:1397-405.

20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,

    and histopathologic features of methotrexate-associated lung injury in patients with

    rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.*

    1997;40:1829-37.

29

21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.

22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.* 2009;68:1100-4.

23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. *Eur Respir J.* 2000;15:373-81.

24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.

25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.

26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am Rev Respir Dis.* 1985;131:770-7.

27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.

28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern

as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.

29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care Med.* 2007;175:705-11.

30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.* 2010;35:1322-8.

31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.

Table 1 Clinical characteristics

Characteristics	Total	Non-AE group[#]	AE group[¶]	P value[+]
	N = 51 (100)	N = 40 (78)	N = 11 (22)	
Median age, years (range)				
at RA diagnosis	61 (28-82)	60 (28-81)	65 (42-82)	0.15
at ILD diagnosis	62 (31-83)	62 (31-83)	69 (58-83)	0.15
at AE onset			72 (60-86)	
Sex Male, n (%)	29 (57)	23 (58)	6 (55)	0.86
Observation period, years (range)	8.5 (1-17)	9 (1-17)	6.4 (2-14)	0.45
AE-free period, years (range)	7(1-17)	9 (1-17)	6 (2-14)	0.19
Smoking habit, n (%)				
Never	20 (39)	18 (45)	2 (18)	
Former	24 (47)	16 (40)	8 (73)	0.15
Current	7 (14)	6 (15)	1 (9)	
RF, IU/mL (range)[*]	197 (6-2666)	189 (6-2666)	205 (39-2530)	0.47
DAS28-CRP, score (range)[*]	1.95(1.02-5.13)	2.53(1.02-5.13)	1.82(1.47-2.3)	0.62
PaO_2, torr (range)	82.4 (67-109)	81 (67-102)	85.8 (74-109)	0.19
%FVC, % (range)	91.1 (50.6-130)	87.5 (51-130)	95 (60-125)	0.38
HRCT pattern, n (%)				
UIP pattern	14 (27)	8 (20)	6 (55)	0.02[§]
non-UIP pattern	37 (73)	32 (80)	5 (45)	
Death during observation period, n (%)				
caused by respiratory failure	8 (16)	2 (5)	7 (64)	0.02[§]
caused by other diseases	4 (8)	3 (8)	0 (0)	

Data are presented as n (%), median (range). AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

[+]Non-AE group vs AE group

[§]$p < 0.05$

[*]at the first AE occurrence (AE group) or the last visit (non-AE group).

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

32

In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding and 2 of unknown causes.

Table 2 Diagnostic accuracy of HRCT pattern for histopathological pattern in 21 histopathologically confirmed patients.

	Histopathological pattern		Total
	UIP	Other pattern	
UIP pattern on HRCT	5	0	5
non-UIP pattern on HRCT	7	9	16
Total	12	9	21

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

	Total N = 51	non-AE group[+] N = 40 (78%)	AE group[§] N = 11 (22%)	P value
Treatment, yes	37 (73)	27(68)	10 (91)	0.12
Corticosteroid	29 (57)	22 (55)	7 (64)	0.61
Immunosuppressant except for MTX	17 (33)	14 (35)	3 (27)	0.63
MTX	10 (20)	4 (10)	6 (55)	0.001[*]
Other drugs	17 (33)	13 (33)	4 (36)	0.81

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cycrophosphaminde (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

[+] Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

[*] $p < 0.05$

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	1.03	0.97-1.10	0.35
Age at ILD diagnosis	1.11	1.02-1.21	0.01[+]
Sex, male	0.90	0.49-1.69	0.73
Smoking habit, yes	1.60	0.81-4.10	0.19
UIP pattern on HRCT, yes	1.95	1.07-3.63	0.03[+]
PaO_2 at ILD diagnosis	1.05	0.98-1.12	0.14
%FVC at ILD diagnosis	1.02	0.99-1.06	0.24
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	0.97	0.53-1.92	0.94
Immunosuppressant except for MTX	0.76	0.35-1.41	0.39
MTX	3.04	1.62-6.02	0.001[+]
Other drugs	0.98	0.50-1.80	0.96

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

36

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	0.98	0.93-1.04	0.48
Age at ILD diagnosis	1.08	0.99-1.17	0.057
Sex, male	1.14	0.63-2.22	0.67
Smoking habit, yes	1.70	0.87-4.35	0.13
UIP pattern on HRCT, yes	1.74	0.97-3.12	0.06
PaO_2 at ILD diagnosis	1.05	0.98-1.11	0.15
%FVC at ILD diagnosis	1.01	0.98-1.04	0.55
AE during observation period, yes	2.47	1.39-4.56	0.003[+]
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	1.23	0.67-2.65	0.52
Immunosuppressant except for MTX	0.69	0.32-1.27	0.25
MTX	1.44	0.67-2.68	0.31
Other drugs	0.76	0.36-1.41	0.40

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

37

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were

excluded, and 51 patients with chronic course of RA-ILD were included. During

observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE

compared with non-UIP pattern on HRCT (log-rank p=0.018).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP,

usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with

those with non-UIP pattern on HRCT (log-rank p=0.04).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

38

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly

worse survival compared with those who did not (non-AE group) (log-rank p=0.001).

AE, acute exacerbation.

39

FIGURE 1.

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE. RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.
80x160mm (300 x 300 DPI)

Title: Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

Authors:

Hironao Hozumi, M.D., Ph.D.[1]

Yutaro Nakamura, M.D., Ph.D.[1]

Takeshi Johkoh, M.D., Ph.D.[2]

Hiromitsu Sumikawa, M.D., Ph.D.[3]

Thomas V. Colby, M.D.[4]

Masato Kono, M.D, Ph.D.[1]

Dai Hashimoto, M.D., Ph.D.[1]

Noriyuki Enomoto, M.D., Ph.D.[1]

Tomoyuki Fujisawa, M.D., Ph.D.[1]

Naoki Inui, M.D., Ph.D.[1]

Takafumi Suda, M.D., Ph.D.[1]

Kingo Chida, M.D., Ph.D.[1]

Affiliations:

[1]Second division, Department of Internal Medicine, Hamamatsu University School of

1

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

[2]Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public

School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

[3]Diagnostic and Interventional Radiology, Osaka University Graduate School of

Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

[4]Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East

Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

2

Word count paper: ~~2779~~3382

Word count abstract: ~~292~~280

3

ABSTRACT

Background   Acute exacerbation (AE) in idiopathic pulmonary fibrosis is

characterised by acute deterioration of respiratory status and the mortality is high.

Recently, AE was reported in patients with other interstitial lung diseases, especially

rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives   To investigate the risk factors and prognosis associated with AE in

patients with RA-ILD.

Design   A retrospective ~~cohort~~case-control study.

Setting   A single academic hospital.

Participants   51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.

All patients fulfilled the diagnostic criteria of the American College of Rheumatology

for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function

tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures   Overall survival and cumulative AE incidence were

analysed using Kaplan–Meier method. Cox hazards analysis was used to determine

significant variables associated with AE occurrence and survival status.

Results   A total of 11 patients (22%) developed AE, with an overall 1-year incidence

of 2.8%. Univariate analysis revealed that higher age at ILD diagnosis [hazard ratio

4

(HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial

pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and

treatment with methotrexate (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were risk factors

for AE. Of 11 patients who developed AE during observation period, seven (64%) died

of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95%

CI, 1.39–4.56; $P = 0.003$).

Conclusions   In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on

HRCT and treatment with methotrexate are risk factors for AE. Furthermore, AE has a

serious impact on their survival. ~~We should carefully observe the patients having any of~~

~~these risk factors.~~

5

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis (IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with RA-ILD?

Key messages;

In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on HRCT, and treatment with methotrexate are risk factors for AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE ~~may have~~has a serious impact on the survival of patients with RA-ILD ~~as well as that with IPF. Thus, the patients with any of these risk factors should be carefully observed~~.

Given its retrospective study design, it is subject to several possible biases. Therefore, prospective studies are necessary to confirm our results.

6

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, and an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is the mostone of common extra-articular manifestations,.[6] with a, 7] The reported prevalence of is variable (1% – 58%.[7-12%) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated

7

ILD (RA-ILD) was the most common CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated with AE in patients with RA-ILD are not clarified.

In the present study, we attempted to elucidate the cumulative incidence of AE, its risk factors, and prognostic factors in patients with RA-ILD.

MATERIALS AND METHODS

Subjects

Institutional review board in Hamamatsu University School of Medicine approved this study (approval number 24-191) and waived patient approval or informed consent because the study involved a retrospective review of patient records and images. We retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995 and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA.[1314] Patients with other coexisting CVD were excluded. In addition, because our aim was to investigate the features of AE among patients with a chronic course of RA-ILD, patients with no evidence of chronic ILD were also excluded.

ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

8

HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities

and honeycomb patterns were interpreted and defined as ILD by a consensus between

radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and

bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to

definitively diagnose ILD or rule out other diseases. The patients with environmental

exposures, suspected of drug induced pneumonia (ILD developed within 1 year after

initiation of new drug), or with other known causes of ILD were excluded after

considering exposure history and the findings of appropriate tests and histopathological

examinations.

Acute exacerbation (AE)

AE was defined using recently proposed criteria[1] that were slightly modified for

adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or

development of dyspnea within 30 days of onset, new bilateral ground-glass

abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern

on HRCT, no evidence of pulmonary infection on negative respiratory culture,

including endotracheal aspirate or bronchoalveolar lavage, and serological test results

for respiratory pathogens, and exclusion of alternative causes such as left heart failure,

9

pulmonary embolism, and an identifiable cause of acute lung injury. Patients with AE

were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,

and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,

fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if

necessary, CT scanning with intravenous contrast were performed to rule out left heart

failure or pulmonary thromboembolism. The patients who developed acute pneumonitis

within 1 year after initiation of drug for RA were excluded because drug-induced

pneumonitis was not completely ruled out. Patients who did or did not develop AE

during the observation period were classified into the AE and non-AE groups,

respectively.

Data collection

All clinical and laboratory data were collected from medical records. The observation

period was calculated from the date of diagnosis of RA-ILD to the last visit. The

AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis

and the first AE occurrence (AE group) or the last visit (non-AE group).

Review of radiographic findings

10

HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images

comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were

reconstructed by a high spatial frequency algorithm, and were displayed at window

settings appropriate for viewing the lung parenchyma (window level, -600 to -800

Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were

randomised and reviewed independently by two expert chest radiologists (with 23 and

12 years of experience) who were unaware of the related clinical information.

Interobserver agreement was classified as follows: poor (κ = 0–0.20), fair (κ =

0.21–0.40), moderate (κ = 0.41–0.60), good (κ = 0.61–0.80) and excellent (κ =

0.81-1.00).

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a

non-UIP pattern according to recent guideline. [14 with slight modification.[15] Briefly,

a UIP pattern on HRCT was characterised by subpleural and basal predominance,

reticular abnormalities, honeycombing with or without traction bronchiectasis and the

absence of features listed as inconsistent with a UIP pattern, including upper or

mid-lung predominance, peribronchovascular predominance, extensive ground glass

abnormalities, profuse micronodules, discrete cysts, diffuse mosaic

attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If

11

the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.

Disagreements regarding HRCT interpretation were resolved by a consensus between

both radiologists.

Review of histopathological findings

SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was

originally made in all cases on the basis of histological features evaluated by a lung

pathologist at our hospital, correlated with the clinical and radiological findings. All

SLB specimens were also reviewed by a second lung pathologist with 36 years of

experience. The histological classification of interstitial pneumonia was based on the

consensus statement criteria for idiopathic interstitial pneumonias,[1516] and

histological patterns that could not be classified according to the criteria were

categorised as unclassified interstitial pneumonia.

Statistical analysis

All values are expressed as median (range) or number (%). The Mann-Whitney U test

was used for nonparametric comparisons involving continuous data, whereas Fisher's

exact test was used for comparing categorical data. Interobserver agreement on HRCT

12

pattern was analyzed using the κ statistic test. ~~Interobserver agreement was classified as follows: poor (κ = 0–0.20), fair (κ = 0.21–0.40), moderate (κ = 0.41–0.60), good (κ = 0.61–0.80) and excellent (κ = 0.81–1.00).~~ Survival was evaluated using the

Kaplan–Meier method and the log-rank test according to observation period. The

cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating

AE as the death variable, according to AE free period. The 1-year AE incidence was

based on person year method and calculated by dividing the number of patients who

developed AE by the total of AE-free period (year) of all the patients. Cox hazards

analysis was used to determine significant variables associated with survival and AE

occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data

were analysed using commercially available software (JMP version 9.0.3a, SAS

Institute Inc, Cary, NC, USA).

RESULTS

Patient characteristics (Table 1)

A total of 82 patients with RA-ILD were identified from medical records at

Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8

with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3

suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom no initial HRCT images were available for review were also excluded. The remaining 51 patients with RA-ILD were included in this study.(Figure 1)

The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82) years and 62 (range, 31–83) years, respectively. The median observation period and AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.

During the observation period, 11 patients (22%) developed AE. The median age at the onset of AE was 72 (range, 60–86) years. There were no statistically significant differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period, AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of RA-ILD, and arterial oxygen pressure (PaO_2) at diagnosis of RA-ILD between the AE and non-AE groups. Also there were no statistically significant differences in articular disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE occurrence (AE group).

In the AE group, seven of 11 patients (64%) died of initial AE during the observation period. In the non-AE group, 52 of 40 patients (135%) died of respiratory failure. There was a statistically significant difference in the mortality rate between the AE and non-AE groups.

14

Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51 patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in 2, glomerulonephritis in 1, rheumatoid nodule in 2). There was no significant difference in the incidence between AE group and non-AE group (27% vs. 13%, P=0.26).

HRCT pattern (Table 1)

Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT. HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%) patients in the AE group demonstrated a UIP pattern. Interobserver agreement between both radiologists was moderate (κ statistic test, $\kappa = 0.44$). The number of patients who exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the non-AE group.

~~Correlation between~~When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

Diagnostic accuracy of HRCT pattern for histopathological ~~findings and HRCT~~

pattern (Table 2)

Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis

revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and

an unclassified interstitial pneumonia in 1. The ~~correlation between~~diagnostic accuracy

of HRCT pattern for histopathological ~~and HRCT~~ pattern was evaluated in 21

histopathologically confirmed patients. When the pattern was identified as a UIP pattern

on HRCT, the sensitivity, specificity, positive predictive value and negative predictive

value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%,

respectively.

Treatment for RA (Table 3)

Of the 51 patients, 37 (73%) had received treatment for RA at their final visit

(non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had

received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10

(20%) received MTX and 17 (33%) received other drugs. ~~The number of~~There were 6

(55%) patients who had received MTX ~~was significantly higher~~ in ~~the~~ AE group

~~than~~while 4 (10%) patients in ~~the~~ non-AE group ~~(55% vs. 10%,~~ and statistically

significant difference was observed between the groups ($P = 0.001$).

16

No patients had received MTX before in AE group while 2 in non-AE group. Thus, there were 6 (55%) patients who had experienced MTX treatment during observation period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE group and 802mg (32-2496) in 6 patients among non-AE group. No statistically significant difference was observed between two groups in cumulative MTX dose (*P*=0.20).

Articular disease activities (RF and DAS28-CRP) were compared between patients who had received MTX at the last visit or at the first AE occurrence, and those who had not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) (*P*=0.25), Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) (*P*=0.78), respectively. There were no statistically significant differences in articular disease activities.

AE incidence

The cumulative AE incidence in patients with RA-ILD is shown in Figure ~~1~~2. The 5-year AE incidence was ~~significantly higher~~11% [95% confidence interval (CI), 2–21%] in all patients, 33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT

17

(UIP pattern group) thanand 3% (95% CI, 0–9%) in patients with a non-UIP pattern on

HRCT (non-UIP pattern group)). The AE incidence was significantly higher in UIP

pattern group than in non-UIP pattern group (log-rank test, $P = 0.018$). The overall

1-year AE incidence was 2.8%. The 1-year AE incidence was 6.5% in the UIP pattern

group and 1.7 % in the non-UIP pattern group.

Univariate analysis (Table 4) revealed that higher age at ILD diagnosis [hazard ratio

(HR), 1.11; 95% confidence interval (CI),CI, 1.02–1.21; $P = 0.01$], UIP pattern on

HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and treatment with MTX (HR, 3.04;

95% CI, 1.62–6.02; $P = 0.001$) were significant risk factors for AE occurrence.

Survival

The overall survival of patients with RA-ILD is shown in Figure 23.

The 5-year survival was 90% (95% CI, 81–98%) in all patients, 70% (95% CI, 44–94%)

in the UIP pattern group and 97% (95% CI, 92–100%) in the non-UIP pattern group.

Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern

group (log-rank test, $P = 0.04$). In addition, significantly worse survival was

demonstrated in the AE group compared with the non-AE group (Figure 34, log-rank

test, $P = 0.001$).

18

Univariate analysis (Table 5) revealed that higher age at ILD diagnosis (HR, 1.08; 95% CI, 0.99–1.17; P = 0.057) and UIP pattern on HRCT (HR, 1.74; 95% CI, 0.97–3.12; P = 0.06) showed a trend toward poor outcome, while AE (HR, 2.47; 95% CI, 1.39–4.56; P = 0.003) was significantly associated with poor survival.

DISCUSSION

To our knowledge, the present study is the first one focusing on the risk factors and prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern on HRCT, MTX treatment and higher age at ILD diagnosis were significant risk factors for AE. Furthermore, AE was a prognostic factor for poor survival.

The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[~~16,~~ 17, 18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 % for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, ~~patients with RA-ILD had a relatively lower incidence of AE. However,~~ the 1-year AE incidence among patients with a UIP pattern on HRCT was 6.5~~%, comparable to that~~% and cumulative incidence was significantly higher in ~~patients with IPF~~UIP pattern group than in non-UIP pattern group. Furthermore, a UIP pattern on HRCT was a risk factor

19

for AE. In a previous report of small number of biopsy-proven cases, AE incidence

among patients with RA-UIP was reported to be 11.1%, also similar to that among

patients with IPF.[4] The correlation between pathological and radiological UIP patterns

has been established in IPF, but not in RA-ILD.[1819] In the present study,

determination of a UIP pattern on HRCT exhibited high specificity and positive

predictive values for the detection of pathological UIP pattern. Therefore, a typical UIP

pattern on HRCT was assumed to be highly suggestive of pathological UIP pattern in

patients with RA-ILD as well as IPF.[14, 1815, 19] Collectively, these results suggest

that AE occurs less frequently in RA-ILD than in IPF, while AE incidence in a subgroup

with pathological UIP pattern or a UIP pattern on HRCT may be as high ashigher than

that in patients with IPF.other patterns..

The present study also identified MTX treatment as a risk factor for AE. MTX is

widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic

criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed

previously.[1920] However, the specificity of the criteria has not been fully examined

yet. MTX-pneumonitis typically occurs with acute/subacute onset early in the course of

MTX treatment,[19-2220-23] in particular, mostly within the first year[2324] and often

presents a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis

generally respond to discontinuation of MTX or corticosteroid treatment and have a favorable prognosis.[~~19-22~~20-23] In the present study, 6 of 11 patients with AE had received MTX, and 5 of the 6 patients had been treated for 3 or more years. The remaining patient had been treated for 1 year. In all 6 patients, their respiratory conditions progressively deteriorated despite discontinuation of MTX, and they poorly responded to high-dose corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment duration and clinical features, we diagnosed these patients with AE of RA-ILD.

Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown; however, several reports have suggested that AE may be a distinct manifestation of the primary disease process, a distinct condition associated with undiagnosed infection, or a subsequent acceleration of a fibroproliferative process caused by acute direct stress to the lung.[1] In the present study, ~~RA joint disease activity~~ DAS28-CRP in all patients with AE ~~was stable~~ showed low disease activity or remission at the time of AE occurrence, and no significant difference in articular disease activities was observed between AE group and non-AE group or regardless of MTX treatment; therefore, RA activity may not be related to AE occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates the fibroproliferative process of RA-ILD. It was

21

reported that MTX treatment was a risk factor for RA-ILD progression.[~~10~~12] For

RA-ILD, MTX may be associated not only with newly developing drug-induced

pneumonitis but also with deterioration of pre-existing ILD, including AE. ~~Therefore,~~

~~we think that MTX treatment should be avoided in RA patients with ILD.~~

The present study found that patients with a UIP pattern on HRCT had significantly

poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic

factor for poor outcome. AE has a serious impact on the survival of patients with

IPF,[~~17~~18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with

these reports, the present study revealed that seven (64%) of 11 patients with AE died of

respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE

group was significantly poorer than that in the non-AE group. Therefore, AE is

suggested to be a predictor of poor prognosis in patients with RA-ILD as well as

patients with IPF.

Other prognostic factors in RA-ILD have been reported, including pathological

UIP,[~~24-28~~25-29] UIP pattern on HRCT,[~~29~~30] and age at RA-ILD onset.[~~30~~31] In the

present study, pathological UIP could not be identified as prognostic factors because the

number of biopsy-proven cases were small. However, we observed similar results

regarding UIP pattern on HRCT and age at RA-ILD onset.

22

In our study, the average time between age at onset of RA and that of RA-ILD was relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In another point of view, since the current authors' institution is regional referral center for interstitial lung disease, referral bias might have increased the proportion of patients with early-stage ILD, leading above results.

This study had several limitations. First, given its retrospective study design, it is subject to several possible biases. For instance, selection and recall bias may exist. Second, because of the relatively small sample size, it may be difficult to determine the precise incidence of AE and the number of event (AE occurrence or death) was too small to perform multivariate analysis. Therefore, larger studies are necessary to confirm our results. Third, because the presence of a UIP pattern on HRCT had low sensitivity and negative predictive value for the detection of pathologic UIP, it was likely that some patients with a non-UIP pattern on HRCT may have had pathological UIP. HRCT criteria used in our study do not aim to detect pathological UIP but to clinically diagnose IPF and to exclude alternative diagnosis.[15] The frequency of honeycombing on HRCT differs between RA-ILD and IPF, and some ILDs by other causes including RA-ILD have some of findings inconsistent with UIP. Therefore,

23

HRCT pattern in RA-ILD may be more frequently interpreted as non-UIP pattern than that in IPF. In our study, 2 of 5 patients with histopathological UIP in the absence of a UIP pattern on HRCT develop AE. Thus, SLB may have to be considered for these patients to make pathological diagnosis and to predict AE. Finally, RA includes a variety of manifestations. Therefore, other comorbidities may have affected the results.

In conclusion, higher age at ILD diagnosis, UIP pattern on HRCT and treatment with MTX are risk factors for AE occurrence in patients with RA-ILD. Furthermore, the mortality associated with AE is high and AE is prognostic factor for poor outcome. AE has a serious impact on the survival of patients with RA-ILD. Thus, we should carefully observe the patients having any of these risk factors. Larger prospective studies investigating acute exacerbations in RA-ILD are indicated.

24

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the

integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed

acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and

analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S.,

and K.C. revised the paper.

All authors approved the paper.

25

Competing interest:

All authors do not have any personal or financial support or involvement with

organization(s) that have financial interest in the subject matter, or any competing

interest.

Funding:

This research received no specific grant from any funding agency in the public,

commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this

study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images.

Copyright:

I *[**Yutaro Nakamura**]* the Corresponding Author of this article contained within the

original manuscript which includes any diagrams & photographs, other illustrative

material, video, film or any other material howsoever submitted by the Contributor(s) at

26

any time and related to the Contribution ("the Contribution") have the right to grant on

behalf of all authors and do grant on behalf of all authors, a licence to the BMJ

Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be

published in BMJ Open and any other BMJ Group products and to exploit all subsidiary

rights, as set out in the licence

27

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.

2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.

3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.

4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.

5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.

6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.

7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722–7.

8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

28

their impact on outcome. Rheumatology (Oxford). 2013;52:99-110.

8. 9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain:

occurrence of extra-articular manifestations and estimates of disease severity. *Ann*

Rheum Dis. 2003;62:897–900.

9. 10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with

rheumatoid arthritis as assessed by high resolution computed tomography, chest

radiography, and pulmonary function tests. *Thorax.* 2001;56:622–7.

10. 11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset

rheumatoid arthritis. *Am J Respir Crit Care Med.* 1997;156:528–35.

11. 12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial

lung disease in rheumatoid arthritis. *Arch Intern Med.* 2008;168:159–66.

12. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on

high-resolution computed tomography in patients with early versus longstanding

rheumatoid arthritis. *J Rheumatol.* 2008;35:1513–21.

13. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease

manifestations in rheumatoid arthritis: incidence trends and risk factors over 46

years. *Ann Rheum Dis.* 2003;62:722–7.

29

14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association

1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.*

1988;31:315-24.

15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on

Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:

idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and

management. *Am J Respir Crit Care Med.* 2011;183:788-824.

16. American Thoracic Society/European Respiratory Society International

Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.

Am J Respir Crit Care Med. 2002;165:277-304.

17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary

fibrosis. *Chest.* 2007;132:1652-8.

18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary

fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.

19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung

disease: the relevance of histopathologic and radiographic pattern. *Chest.*

2009;136:1397-405.

30

20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.* 1997;40:1829-37.

21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.

22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.* 2009;68:1100-4.

23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. *Eur Respir J.* 2000;15:373-81.

24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.

25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.

26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am*

Rev Respir Dis. 1985;131:770-7.

27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.

28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.

29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care Med.* 2007;175:705-11.

30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.* 2010;35:1322-8.

31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.

32

Table 1 Clinical characteristics

Characteristics	Total N = 51 (100)	Non-AE group[#] N = 40 (78)	AE group[¶] N = 11 (22)	P value[+]
Median age, years (range)				
at RA diagnosis	61 (28-82)	60 (28-81)	65 (42-82)	0.15
at ILD diagnosis	62 (31-83)	62 (31-83)	69 (58-83)	0.15
at AE onset			72 (60-86)	
Sex Male, n (%)	29 (57)	23 (58)	6 (55)	0.86
Observation period, years (range)	8.5 (1-17)	9 (1-17)	6.4 (2-14)	0.45
AE-free period, years (range)	7(1-17)	9 (1-17)	6 (2-14)	0.19
Smoking habit, n (%)				
Never	20 (39)	18 (45)	2 (18)	
Former	24 (47)	16 (40)	8 (73)	0.15
Current	7 (14)	6 (15)	1 (9)	
RF, IU/mL (range)[*]	197 (6-2666)	189 (6-2666)	205 (39-2530)	0.47
DAS28-CRP, score (range)[*]	1.95(1.02-5.13)	2.53(1.02-5.13)	1.82(1.47-2.3)	0.62
PaO$_2$, torr (range)	82.4 (67-109)	81 (67-102)	85.8 (74-109)	0.19
%FVC, % (range)	91.1 (50.6-130)	87.5 (51-130)	95 (60-125)	0.38
HRCT pattern, n (%)				
UIP pattern	14 (27)	8 (20)	6 (55)	0.02[§]
non-UIP pattern	37 (73)	32 (80)	5 (45)	
Death during observation period, n (%)	12 (24)	5 (13)	7 (64)	0.001[§]
caused by respiratory failure	8 (16)	2 (5)	7 (64)	0.02[§]
caused by other diseases	4 (8)	3 (8)	0 (0)	

Data are presented as n (%), median (range).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO$_2$, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶] AE group, patients who developed AE during observation period.

[+] Non-AE group vs AE group

[§] $p < 0.05$

[*] at the first AE occurrence (AE group) or the last visit (non-AE group).

33

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding and 2 of unknown causes.

34

Table 2 ~~Correlation between~~Diagnostic accuracy of HRCT pattern for histopathological ~~findings and HRCT~~ pattern in 21 histopathologically confirmed patients.

	Histopathological pattern		Total
	UIP	Other pattern	
UIP pattern on HRCT	5	0	5
non-UIP pattern on HRCT	7	9	16
Total	12	9	21

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

35

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

	Total	non-AE group[+]	AE group[§]	P value
	N = 51	N = 40 (78%)	N = 11 (22%)	
Treatment, yes	37 (73)	27(68)	10 (91)	0.12
Corticosteroid	29 (57)	22 (55)	7 (64)	0.61
Immunosuppressant except for MTX	17 (33)	14 (35)	3 (27)	0.63
MTX	10 (20)	4 (10)	6 (55)	0.001[*]
Other drugs	17 (33)	13 (33)	4 (36)	0.81

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cycrophosphaminde (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

[+] Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

[*] $p < 0.05$

36

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	1.03	0.97-1.10	0.35
Age at ILD diagnosis	1.11	1.02-1.21	0.01[+]
Sex, male	0.90	0.49-1.69	0.73
Smoking habit, yes	1.60	0.81-4.10	0.19
UIP pattern on HRCT, yes	1.95	1.07-3.63	0.03[+]
PaO_2 at ILD diagnosis	1.05	0.98-1.12	0.14
%FVC at ILD diagnosis	1.02	0.99-1.06	0.24
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	0.97	0.53-1.92	0.94
Immunosuppressant except for MTX	0.76	0.35-1.41	0.39
MTX	3.04	1.62-6.02	0.001[+]
Other drugs	0.98	0.50-1.80	0.96

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT,

high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital

capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence

interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

37

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	0.98	0.93-1.04	0.48
Age at ILD diagnosis	1.08	0.99-1.17	0.057
Sex, male	1.14	0.63-2.22	0.67
Smoking habit, yes	1.70	0.87-4.35	0.13
UIP pattern on HRCT, yes	1.74	0.97-3.12	0.06
PaO_2 at ILD diagnosis	1.05	0.98-1.11	0.15
%FVC at ILD diagnosis	1.01	0.98-1.04	0.55
AE during observation period, yes	2.47	1.39-4.56	0.003[+]
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	1.23	0.67-2.65	0.52
Immunosuppressant except for MTX	0.69	0.32-1.27	0.25
MTX	1.44	0.67-2.68	0.31
Other drugs	0.76	0.36-1.41	0.40

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

38

Figure legends

Figure 1. <u>Numbers of patients included in this study.</u>

<u>82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were</u>

<u>excluded, and 51 patients with chronic course of RA-ILD were included. During</u>

<u>observation period, 11 patients developed AE.</u>

<u>RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.</u>

<u>Figure 2.</u> Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE

compared with non-UIP pattern on HRCT (log-rank p=0.018).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP,

usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure ~~2~~3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with

those with non-UIP pattern on HRCT (log-rank p=0.04).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

39

Figure ~~3~~4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly

worse survival compared with those who did not (non-AE group) (log-rank *p*=0.001).

AE, acute exacerbation.

FIGURE 2.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank p=0.018).
AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
80x80mm (300 x 300 DPI)

FIGURE 3.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank p=0.04).
UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
80x80mm (300 x 300 DPI)

FIGURE 4.

Figure 4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly worse survival
compared with those who did not (non-AE group) (log-rank p=0.001).
AE, acute exacerbation.
80x80mm (300 x 300 DPI)

Title: Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

Authors:

Hironao Hozumi, M.D., Ph.D.[1]

Yutaro Nakamura, M.D., Ph.D.[1]

Takeshi Johkoh, M.D., Ph.D.[2]

Hiromitsu Sumikawa, M.D., Ph.D.[3]

Thomas V. Colby, M.D.[4]

Masato Kono, M.D, Ph.D.[1]

Dai Hashimoto, M.D., Ph.D.[1]

Noriyuki Enomoto, M.D., Ph.D.[1]

Tomoyuki Fujisawa, M.D., Ph.D.[1]

Naoki Inui, M.D., Ph.D.[1]

Takafumi Suda, M.D., Ph.D.[1]

Kingo Chida, M.D., Ph.D.[1]

Affiliations:

[1]Second division, Department of Internal Medicine, Hamamatsu University School of

1

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

[2]Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public

School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

[3]Diagnostic and Interventional Radiology, Osaka University Graduate School of

Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

[4]Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East

Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

2

Word count paper: 3382

Word count abstract: 280

3

ABSTRACT

Background   Acute exacerbation (AE) in idiopathic pulmonary fibrosis is characterised by acute deterioration of respiratory status and the mortality is high. Recently, AE was reported in patients with other interstitial lung diseases, especially rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives   To investigate the risk factors and prognosis associated with AE in patients with RA-ILD.

Design   A retrospective case-control study.

Setting   A single academic hospital.

Participants   51 consecutive patients diagnosed with RA-ILD between 1995 and 2012. All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures   Overall survival and cumulative AE incidence were analysed using Kaplan–Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status.

Results   A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that higher age at ILD diagnosis [hazard ratio

4

(HR), 1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial

pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and

treatment with methotrexate (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were risk factors

for AE. Of 11 patients who developed AE during observation period, seven (64%) died

of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95%

CI, 1.39–4.56; $P = 0.003$).

Conclusions In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on

HRCT and treatment with methotrexate are risk factors for AE. Furthermore, AE has a

serious impact on their survival.

5

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis

(IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease

(RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with

RA-ILD?

Key messages;

In patients with RA-ILD, higher age at ILD diagnosis, UIP pattern on HRCT, and

treatment with methotrexate are risk factors for AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE has a serious impact on the survival of patients with RA-ILD.

Given its retrospective study design, it is subject to several possible biases. Therefore,

prospective studies are necessary to confirm our results.

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised

occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute

deterioration in respiratory status, with newly developed bilateral ground-glass opacities

and/or consolidations on chest radiographs or computed tomography scans. It should be

in the absence of other alternative causes such as infection, left heart failure, pulmonary

embolism, and an identifiable cause of acute lung injury. AE reportedly occurs not only

in patients with IPF but also in patients with other interstitial lung diseases (ILDs),

including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular

disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital

mortality associated with AE in patients with CVD-ILD was demonstrated to be as high

as that in patients with IPF,[1-4] suggesting that AE may be associated with poor

prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown

etiology that primarily involves joints.[5] ILD is one of common extra-articular

manifestations.[6, 7] The reported prevalence is variable (1–58%) and depends on the

detection and diagnostic method, or the selected population.[8-13] We and Park *et al*

previously reported that RA-associated ILD (RA-ILD) was the most common

7

CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated

with AE in patients with RA-ILD are not clarified.

In the present study, we attempted to elucidate the cumulative incidence of AE, its

risk factors, and prognostic factors in patients with RA-ILD.

MATERIALS AND METHODS

Subjects

Institutional review board in Hamamatsu University School of Medicine approved

this study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images. We

retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995

and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the

diagnostic criteria of the American College of Rheumatology for RA.[14] Patients with

other coexisting CVD were excluded. In addition, because our aim was to investigate

the features of AE among patients with a chronic course of RA-ILD, patients with no

evidence of chronic ILD were also excluded.

ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,

high resolution computed tomography (HRCT) findings, and lung biopsy findings.

8

HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities

and honeycomb patterns were interpreted and defined as ILD by a consensus between

radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and

bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to

definitively diagnose ILD or rule out other diseases. The patients with environmental

exposures, suspected of drug induced pneumonia (ILD developed within 1 year after

initiation of new drug), or with other known causes of ILD were excluded after

considering exposure history and the findings of appropriate tests and histopathological

examinations.

Acute exacerbation (AE)

AE was defined using recently proposed criteria[1] that were slightly modified for

adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or

development of dyspnea within 30 days of onset, new bilateral ground-glass

abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern

on HRCT, no evidence of pulmonary infection on negative respiratory culture,

including endotracheal aspirate or bronchoalveolar lavage, and serological test results

for respiratory pathogens, and exclusion of alternative causes such as left heart failure,

9

pulmonary embolism, and an identifiable cause of acute lung injury. Patients with AE

were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,

and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,

fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if

necessary, CT scanning with intravenous contrast were performed to rule out left heart

failure or pulmonary thromboembolism. The patients who developed acute pneumonitis

within 1 year after initiation of drug for RA were excluded because drug-induced

pneumonitis was not completely ruled out. Patients who did or did not develop AE

during the observation period were classified into the AE and non-AE groups,

respectively.

Data collection

All clinical and laboratory data were collected from medical records. The observation

period was calculated from the date of diagnosis of RA-ILD to the last visit. The

AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis

and the first AE occurrence (AE group) or the last visit (non-AE group).

Review of radiographic findings

10

HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were reconstructed by a high spatial frequency algorithm, and were displayed at window settings appropriate for viewing the lung parenchyma (window level, -600 to -800 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were randomised and reviewed independently by two expert chest radiologists (with 23 and 12 years of experience) who were unaware of the related clinical information. Interobserver agreement was classified as follows: poor ($\kappa = 0$–0.20), fair ($\kappa = 0.21$–0.40), moderate ($\kappa = 0.41$–0.60), good ($\kappa = 0.61$–0.80) and excellent ($\kappa = 0.81$-1.00).

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a non-UIP pattern according to recent guideline with slight modification.[15] Briefly, a UIP pattern on HRCT was characterised by subpleural and basal predominance, reticular abnormalities, honeycombing with or without traction bronchiectasis and the absence of features listed as inconsistent with a UIP pattern, including upper or mid-lung predominance, peribronchovascular predominance, extensive ground glass abnormalities, profuse micronodules, discrete cysts, diffuse mosaic attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If

11

the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.

Disagreements regarding HRCT interpretation were resolved by a consensus between

both radiologists.

Review of histopathological findings

SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was

originally made in all cases on the basis of histological features evaluated by a lung

pathologist at our hospital, correlated with the clinical and radiological findings. All

SLB specimens were also reviewed by a second lung pathologist with 36 years of

experience. The histological classification of interstitial pneumonia was based on the

consensus statement criteria for idiopathic interstitial pneumonias,[16] and histological

patterns that could not be classified according to the criteria were categorised as

unclassified interstitial pneumonia.

Statistical analysis

All values are expressed as median (range) or number (%). The Mann-Whitney U test

was used for nonparametric comparisons involving continuous data, whereas Fisher's

exact test was used for comparing categorical data. Interobserver agreement on HRCT

12

pattern was analyzed using the κ statistic test. Survival was evaluated using the

Kaplan–Meier method and the log-rank test according to observation period. The

cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating

AE as the death variable according to AE free period. The 1-year AE incidence was

based on person year method and calculated by dividing the number of patients who

developed AE by the total of AE-free period (year) of all the patients. Cox hazards

analysis was used to determine significant variables associated with survival and AE

occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data

were analysed using commercially available software (JMP version 9.0.3a, SAS

Institute Inc, Cary, NC, USA).

RESULTS

Patient characteristics (Table 1)

A total of 82 patients with RA-ILD were identified from medical records at

Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8

with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3

suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom

no initial HRCT images were available for review were also excluded. The remaining

13

51 patients with RA-ILD were included in this study.(Figure 1)

The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)

years and 62 (range, 31–83) years, respectively. The median observation period and

AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.

During the observation period, 11 patients (22%) developed AE. The median age at

the onset of AE was 72 (range, 60–86) years. There were no statistically significant

differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,

AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of

RA-ILD, and arterial oxygen pressure (PaO_2) at diagnosis of RA-ILD between the AE

and non-AE groups. Also there were no statistically significant differences in articular

disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE

occurrence (AE group).

In the AE group, seven of 11 patients (64%) died of initial AE during the observation

period. In the non-AE group, 2 of 40 patients (5%) died of respiratory failure. There was

a statistically significant difference in the mortality rate between the AE and non-AE

groups.

Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51

patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in

14

2, glomerulonephritis in 1, rheumatoid nodule in 2). There was no significant difference

in the incidence between AE group and non-AE group (27% vs. 13%, *P*=0.26).

HRCT pattern (Table 1)

Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.

HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)

patients in the AE group demonstrated a UIP pattern. Interobserver agreement between

both radiologists was moderate (κ statistic test, κ = 0.44). The number of patients who

exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the

non-AE group.

When HRCT pattern was identified as a UIP pattern, the positive predictive value and

negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

Diagnostic accuracy of HRCT pattern for histopathological pattern (Table 2)

Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis

revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and

an unclassified interstitial pneumonia in 1. The diagnostic accuracy of HRCT pattern for

histopathological pattern was evaluated in 21 histopathologically confirmed patients.

15

When the pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%, 100% and 56.3%, respectively.

Treatment for RA (Table 3)

Of the 51 patients, 37 (73%) had received treatment for RA at their final visit (non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10 (20%) received MTX and 17 (33%) received other drugs. There were 6 (55%) patients who had received MTX in AE group while 4 (10%) patients in non-AE group and statistically significant difference was observed between the groups ($P = 0.001$).

No patients had received MTX before in AE group while 2 in non-AE group. Thus, there were 6 (55%) patients who had experienced MTX treatment during observation period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE group and 802mg (32-2496) in 6 patients among non-AE group. No statistically significant difference was observed between two groups in cumulative MTX dose (P=0.20).

16

Articular disease activities (RF and DAS28-CRP) were compared between patients who had received MTX at the last visit or at the first AE occurrence, and those who had not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) (*P*=0.25), Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) (*P*=0.78), respectively. There were no statistically significant differences in articular disease activities.

AE incidence

The cumulative AE incidence in patients with RA-ILD is shown in Figure 2. The 5-year AE incidence was 11% [95% confidence interval (CI), 2–21%] in all patients, 33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT (UIP pattern group) and 3% (95% CI, 0–9%) in patients with a non-UIP pattern on HRCT (non-UIP pattern group). The AE incidence was significantly higher in UIP pattern group than in non-UIP pattern group (log-rank test, *P* = 0.018). The overall 1-year AE incidence was 2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the non-UIP pattern group.

Univariate analysis (Table 4) revealed that higher age at ILD diagnosis [hazard ratio (HR), 1.11; 95% CI, 1.02–1.21; *P* = 0.01], UIP pattern on HRCT (HR, 1.95; 95% CI,

17

1.07–3.63; P = 0.03) and treatment with MTX (HR, 3.04; 95% CI, 1.62–6.02; P =

0.001) were significant risk factors for AE occurrence.

Survival

The overall survival of patients with RA-ILD is shown in Figure 3.

The 5-year survival was 90% (95% CI, 81–98%) in all patients, 70% (95% CI, 44–94%)

in the UIP pattern group and 97% (95% CI, 92–100%) in the non-UIP pattern group.

Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern

group (log-rank test, P = 0.04). In addition, significantly worse survival was

demonstrated in the AE group compared with the non-AE group (Figure 4, log-rank test,

P = 0.001).

Univariate analysis (Table 5) revealed that higher age at ILD diagnosis (HR, 1.08;

95% CI, 0.99–1.17; P = 0.057) and UIP pattern on HRCT (HR, 1.74; 95% CI,

0.97–3.12; P = 0.06) showed a trend toward poor outcome, while AE (HR, 2.47; 95%

CI, 1.39–4.56; P = 0.003) was significantly associated with poor survival.

DISCUSSION

To our knowledge, the present study is the first one focusing on the risk factors and

18

prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence

was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern

on HRCT, MTX treatment and higher age at ILD diagnosis were significant risk factors

for AE. Furthermore, AE was a prognostic factor for poor survival.

The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[17,

18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 %

for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, the 1-year AE incidence

among patients with a UIP pattern on HRCT was 6.5% and cumulative incidence was

significantly higher in UIP pattern group than in non-UIP pattern group. Furthermore, a

UIP pattern on HRCT was a risk factor for AE. In a previous report of small number of

biopsy-proven cases, AE incidence among patients with RA-UIP was reported to be

11.1%, similar to that among patients with IPF.[4] The correlation between pathological

and radiological UIP patterns has been established in IPF, but not in RA-ILD.[19] In the

present study, determination of a UIP pattern on HRCT exhibited high specificity and

positive predictive values for the detection of pathological UIP pattern. Therefore, a

typical UIP pattern on HRCT was assumed to be highly suggestive of pathological UIP

pattern in patients with RA-ILD as well as IPF.[15, 19] Collectively, these results

suggest that AE incidence in a subgroup with pathological UIP pattern or a UIP pattern

19

on HRCT may be higher than that in other patterns..

The present study also identified MTX treatment as a risk factor for AE. MTX is widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed previously.[20] However, the specificity of the criteria has not been fully examined yet. MTX-pneumonitis typically occurs with acute/subacute onset early in the course of MTX treatment,[20-23] in particular, mostly within the first year[24] and often presents a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis generally respond to discontinuation of MTX or corticosteroid treatment and have a favorable prognosis.[20-23] In the present study, 6 of 11 patients with AE had received MTX, and 5 of the 6 patients had been treated for 3 or more years. The remaining patient had been treated for 1 year. In all 6 patients, their respiratory conditions progressively deteriorated despite discontinuation of MTX, and they poorly responded to high-dose corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment duration and clinical features, we diagnosed these patients with AE of RA-ILD.

Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown; however, several reports have suggested that AE may be a distinct manifestation of the primary disease process, a distinct condition associated with undiagnosed infection, or a

20

subsequent acceleration of a fibroproliferative process caused by acute direct stress to the lung.[1] In the present study, DAS28-CRP in all patients with AE showed low disease activity or remission at the time of AE occurrence, and no significant difference in articular disease activities was observed between AE group and non-AE group or regardless of MTX treatment; therefore, RA activity may not be related to AE occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates the fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk factor for RA-ILD progression.[12] For RA-ILD, MTX may be associated not only with newly developing drug-induced pneumonitis but also with deterioration of pre-existing ILD, including AE.

The present study found that patients with a UIP pattern on HRCT had significantly poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic factor for poor outcome. AE has a serious impact on the survival of patients with IPF,[18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these reports, the present study revealed that seven (64%) of 11 patients with AE died of respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE group was significantly poorer than that in the non-AE group. Therefore, AE is suggested to be a predictor of poor prognosis in patients with RA-ILD as well as

21

patients with IPF.

Other prognostic factors in RA-ILD have been reported, including pathological

UIP,[25-29] UIP pattern on HRCT,[30] and age at RA-ILD onset.[31] In the present

study, pathological UIP could not be identified as prognostic factors because the number

of biopsy-proven cases were small. However, we observed similar results regarding UIP

pattern on HRCT and age at RA-ILD onset.

In our study, the average time between age at onset of RA and that of RA-ILD was

relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported

that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In

another point of view, since the current authors' institution is regional referral center for

interstitial lung disease, referral bias might have increased the proportion of patients

with early-stage ILD, leading above results.

This study had several limitations. First, given its retrospective study design, it is

subject to several possible biases. For instance, selection and recall bias may exist.

Second, because of the relatively small sample size, it may be difficult to determine the

precise incidence of AE and the number of event (AE occurrence or death) was too

small to perform multivariate analysis. Therefore, larger studies are necessary to

confirm our results. Third, because the presence of a UIP pattern on HRCT had low

22

sensitivity and negative predictive value for the detection of pathologic UIP, it was

likely that some patients with a non-UIP pattern on HRCT may have had pathological

UIP. HRCT criteria used in our study do not aim to detect pathological UIP but to

clinically diagnose IPF and to exclude alternative diagnosis.[15] The frequency of

honeycombing on HRCT differs between RA-ILD and IPF, and some ILDs by other

causes including RA-ILD have some of findings inconsistent with UIP. Therefore,

HRCT pattern in RA-ILD may be more frequently interpreted as non-UIP pattern than

that in IPF. In our study, 2 of 5 patients with histopathological UIP in the absence of a

UIP pattern on HRCT develop AE. Thus, SLB may have to be considered for these

patients to make pathological diagnosis and to predict AE. Finally, RA includes a

variety of manifestations. Therefore, other comorbidities may have affected the results.

In conclusion, higher age at ILD diagnosis, UIP pattern on HRCT and treatment with

MTX are risk factors for AE occurrence in patients with RA-ILD. Furthermore, the

mortality associated with AE is high and AE is prognostic factor for poor outcome.

Larger prospective studies investigating acute exacerbations in RA-ILD are indicated.

23

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the

integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed

acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and

analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S.,

and K.C. revised the paper.

All authors approved the paper.

24

Competing interest:

All authors do not have any personal or financial support or involvement with

organization(s) that have financial interest in the subject matter, or any competing

interest.

Funding:

This research received no specific grant from any funding agency in the public,

commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this

study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images.

Copyright:

I *[Yutaro Nakamura*] the Corresponding Author of this article contained within the

original manuscript which includes any diagrams & photographs, other illustrative

material, video, film or any other material howsoever submitted by the Contributor(s) at

25

any time and related to the Contribution ("the Contribution") have the right to grant on

behalf of all authors and do grant on behalf of all authors, a licence to the BMJ

Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be

published in BMJ Open and any other BMJ Group products and to exploit all subsidiary

rights, as set out in the licence

26

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.

2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.

3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.

4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.

5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.

6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.

7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722–7.

8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

27

their impact on outcome. Rheumatology (Oxford). 2013;52:99-110.

9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. *Ann Rheum Dis.* 2003;62:897–900.

10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. *Thorax.* 2001;56:622–7.

11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. *Am J Respir Crit Care Med.* 1997;156:528–35.

12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. *Arch Intern Med.* 2008;168:159–66.

13. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. *J Rheumatol.* 2008;35:1513–21.

14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988;31:315-24.

28

15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011;183:788-824.

16. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. *Am J Respir Crit Care Med.* 2002;165:277-304.

17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary fibrosis. *Chest.* 2007;132:1652-8.

18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.

19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. *Chest.* 2009;136:1397-405.

20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.* 1997;40:1829-37.

29

21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.

22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.* 2009;68:1100-4.

23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. *Eur Respir J.* 2000;15:373-81.

24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.

25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.

26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am Rev Respir Dis.* 1985;131:770-7.

27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.

28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern

30

as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.

29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia:

idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care*

Med. 2007;175:705-11.

30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in

rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.*

2010;35:1322-8.

31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study).

Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an

inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.

31

Table 1 Clinical characteristics

Characteristics	Total	Non-AE group[#]	AE group[¶]	P value[+]
	N = 51 (100)	N = 40 (78)	N = 11 (22)	
Median age, years (range)				
at RA diagnosis	61 (28-82)	60 (28-81)	65 (42-82)	0.15
at ILD diagnosis	62 (31-83)	62 (31-83)	69 (58-83)	0.15
at AE onset			72 (60-86)	
Sex Male, n (%)	29 (57)	23 (58)	6 (55)	0.86
Observation period, years (range)	8.5 (1-17)	9 (1-17)	6.4 (2-14)	0.45
AE-free period, years (range)	7(1-17)	9 (1-17)	6 (2-14)	0.19
Smoking habit, n (%)				
Never	20 (39)	18 (45)	2 (18)	
Former	24 (47)	16 (40)	8 (73)	0.15
Current	7 (14)	6 (15)	1 (9)	
RF, IU/mL (range)[*]	197 (6-2666)	189 (6-2666)	205 (39-2530)	0.47
DAS28-CRP, score (range)[*]	1.95(1.02-5.13)	2.53(1.02-5.13)	1.82(1.47-2.3)	0.62
PaO_2, torr (range)	82.4 (67-109)	81 (67-102)	85.8 (74-109)	0.19
%FVC, % (range)	91.1 (50.6-130)	87.5 (51-130)	95 (60-125)	0.38
HRCT pattern, n (%)				
UIP pattern	14 (27)	8 (20)	6 (55)	0.02[§]
non-UIP pattern	37 (73)	32 (80)	5 (45)	
Death during observation period, n (%)				
caused by respiratory failure	8 (16)	2 (5)	7 (64)	0.02[§]
caused by other diseases	4 (8)	3 (8)	0 (0)	

Data are presented as n (%), median (range). AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶] AE group, patients who developed AE during observation period.

[+] Non-AE group vs AE group

[§] $p < 0.05$

[*] at the first AE occurrence (AE group) or the last visit (non-AE group).

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

32

In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding and 2 of unknown causes.

33

Table 2 Diagnostic accuracy of HRCT pattern for histopathological pattern in 21
histopathologically confirmed patients.

	Histopathological pattern		Total
	UIP	Other pattern	
UIP pattern on HRCT	5	0	5
non-UIP pattern on HRCT	7	9	16
Total	12	9	21

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial
pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

When HRCT pattern was identified as a UIP pattern on HRCT, the sensitivity, specificity, positive
predictive value and negative predictive value for detecting histopathological UIP was 41.7%, 100%,
100% and 56.3%, respectively.

34

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

	Total	non-AE group[+]	AE group[§]	P value
	N = 51	N = 40 (78%)	N = 11 (22%)	
Treatment, yes	37 (73)	27(68)	10 (91)	0.12
Corticosteroid	29 (57)	22 (55)	7 (64)	0.61
Immunosuppressant except for MTX	17 (33)	14 (35)	3 (27)	0.63
MTX	10 (20)	4 (10)	6 (55)	0.001[*]
Other drugs	17 (33)	13 (33)	4 (36)	0.81

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cycrophosphaminde (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

[+] Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

[*] $p < 0.05$

35

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	1.03	0.97-1.10	0.35
Age at ILD diagnosis	1.11	1.02-1.21	0.01[+]
Sex, male	0.90	0.49-1.69	0.73
Smoking habit, yes	1.60	0.81-4.10	0.19
UIP pattern on HRCT, yes	1.95	1.07-3.63	0.03[+]
PaO_2 at ILD diagnosis	1.05	0.98-1.12	0.14
%FVC at ILD diagnosis	1.02	0.99-1.06	0.24
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	0.97	0.53-1.92	0.94
Immunosuppressant except for MTX	0.76	0.35-1.41	0.39
MTX	3.04	1.62-6.02	0.001[+]
Other drugs	0.98	0.50-1.80	0.96

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT,

high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital

capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence

interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

36

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	0.98	0.93-1.04	0.48
Age at ILD diagnosis	1.08	0.99-1.17	0.057
Sex, male	1.14	0.63-2.22	0.67
Smoking habit, yes	1.70	0.87-4.35	0.13
UIP pattern on HRCT, yes	1.74	0.97-3.12	0.06
PaO_2 at ILD diagnosis	1.05	0.98-1.11	0.15
%FVC at ILD diagnosis	1.01	0.98-1.04	0.55
AE during observation period, yes	2.47	1.39-4.56	0.003[+]
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	1.23	0.67-2.65	0.52
Immunosuppressant except for MTX	0.69	0.32-1.27	0.25
MTX	1.44	0.67-2.68	0.31
Other drugs	0.76	0.36-1.41	0.40

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

37

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were

excluded, and 51 patients with chronic course of RA-ILD were included. During

observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE

compared with non-UIP pattern on HRCT (log-rank p=0.018).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP,

usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with

those with non-UIP pattern on HRCT (log-rank p=0.04).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

38

Figure 4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly

worse survival compared with those who did not (non-AE group) (log-rank p=0.001).

AE, acute exacerbation.

39

Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

SCHOLARONE™
Manuscripts

Title: Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

Authors:

Hironao Hozumi, M.D., Ph.D.[1]

Yutaro Nakamura, M.D., Ph.D.[1]

Takeshi Johkoh, M.D., Ph.D.[2]

Hiromitsu Sumikawa, M.D., Ph.D.[3]

Thomas V. Colby, M.D.[4]

Masato Kono, M.D, Ph.D.[1]

Dai Hashimoto, M.D., Ph.D.[1]

Noriyuki Enomoto, M.D., Ph.D.[1]

Tomoyuki Fujisawa, M.D., Ph.D.[1]

Naoki Inui, M.D., Ph.D.[1]

Takafumi Suda, M.D., Ph.D.[1]

Kingo Chida, M.D., Ph.D.[1]

Affiliations:

[1]Second division, Department of Internal Medicine, Hamamatsu University School of

1

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

[2]Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public

School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

[3]Diagnostic and Interventional Radiology, Osaka University Graduate School of

Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

[4]Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East

Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

2

Word count paper: 3494

Word count abstract: 279

ABSTRACT

Background   Acute exacerbation (AE) in idiopathic pulmonary fibrosis is characterised by acute deterioration of respiratory status and the mortality is high. Recently, AE was reported in patients with other interstitial lung diseases, especially rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives   To investigate the risk factors and prognosis associated with AE in patients with RA-ILD.

Design   A retrospective case-control study.

Setting   A single academic hospital.

Participants   51 consecutive patients diagnosed with RA-ILD between 1995 and 2012. All patients fulfilled the diagnostic criteria of the American College of Rheumatology for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures   Overall survival and cumulative AE incidence were analysed using Kaplan–Meier method. Cox hazards analysis was used to determine significant variables associated with AE occurrence and survival status.

Results   A total of 11 patients (22%) developed AE, with an overall 1-year incidence of 2.8%. Univariate analysis revealed that older age at ILD diagnosis [hazard ratio (HR),

4

1.11; 95% confidence interval (CI), 1.02–1.21; $P = 0.01$], usual interstitial pneumonia

(UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; $P = 0.03$) and methotrexate

usage (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were associated with AE. Of 11

patients who developed AE during observation period, seven (64%) died of initial AE.

In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95% CI,

1.39–4.56; $P = 0.003$).

Conclusions   In patients with RA-ILD, older age at ILD diagnosis, UIP pattern on

HRCT and methotrexate usage are associated with the development of AE. Furthermore,

AE has a serious impact on their survival.

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis

(IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease

(RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with

RA-ILD?

Key messages;

In patients with RA-ILD, older age at ILD diagnosis, UIP pattern on HRCT and

methotrexate usage are associated with AE occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE has a serious impact on the survival of patients with RA-ILD.

Given its retrospective study design, it is subject to several possible biases. Therefore,

prospective studies are necessary to confirm our results.

6

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, or an identifiable cause of lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is one of common extra-articular manifestations.[6, 7] The reported prevalence is variable (1–58%) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common

7

CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated

with AE in patients with RA-ILD are not clarified.

In the present study, we attempted to elucidate the cumulative incidence of AE, its

risk factors, and prognostic factors in patients with RA-ILD.

MATERIALS AND METHODS

Subjects

Institutional review board in Hamamatsu University School of Medicine approved

this study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images. We

retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995

and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the

diagnostic criteria of the American College of Rheumatology for RA.[14] Patients with

other coexisting CVD were excluded. In addition, because our aim was to investigate

the features of AE among patients with a chronic course of RA-ILD, patients with no

evidence of chronic ILD were also excluded. Chronic ILD was defined as the ILD

which had been stable for over 3 months.

ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,

8

high resolution computed tomography (HRCT) findings, and lung biopsy findings.

HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities

and honeycomb patterns were interpreted and defined as ILD by a consensus between

radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and

bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to

definitively diagnose ILD or rule out other diseases. The patients with environmental

exposures, suspected of drug induced pneumonia (ILD developed within 1 year after

initiation of new drug), or with other known causes of ILD were excluded after

considering exposure history and the findings of appropriate tests and histopathological

examinations.

Acute exacerbation (AE)

AE was defined using recently proposed criteria[1] that were slightly modified for

adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or

development of dyspnea within 30 days of onset, new bilateral ground-glass

abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern

on HRCT, no evidence of pulmonary infection on negative respiratory culture,

including endotracheal aspirate or bronchoalveolar lavage, and serological test results

9

for respiratory pathogens, and exclusion of alternative causes such as left heart failure, pulmonary embolism, or an identifiable cause of lung injury. Patients with AE were required to meet all five criteria. In our institution, cultures of sputum, blood, urine, and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria, fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if necessary, CT scanning with intravenous contrast were performed to rule out left heart failure or pulmonary thromboembolism. The patients who developed acute pneumonitis within 1 year after initiation of drug for RA were excluded because drug-induced pneumonitis was not completely ruled out. Patients who did or did not develop AE during the observation period were classified into the AE and non-AE groups, respectively.

Data collection

All clinical and laboratory data were collected from medical records. The observation period was calculated from the date of diagnosis of RA-ILD to the last visit. The AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis and the first AE occurrence (AE group) or the last visit (non-AE group).

10

Review of radiographic findings

HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were reconstructed by a high spatial frequency algorithm, and were displayed at window settings appropriate for viewing the lung parenchyma (window level, -600 to -800 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were randomised and reviewed independently by two expert chest radiologists (with 23 and 12 years of experience) who were unaware of the related clinical information. Interobserver agreement was classified as follows: poor ($\kappa = 0$–0.20), fair ($\kappa = 0.21$–0.40), moderate ($\kappa = 0.41$–0.60), good ($\kappa = 0.61$–0.80) and excellent ($\kappa = 0.81$-1.00).

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a non-UIP pattern according to recent guideline with slight modification.[15] Briefly, a UIP pattern on HRCT was characterised by subpleural and basal predominance, reticular abnormalities, honeycombing with or without traction bronchiectasis and the absence of features listed as inconsistent with a UIP pattern, including upper or mid-lung predominance, peribronchovascular predominance, extensive ground glass abnormalities, profuse micronodules, discrete cysts, diffuse mosaic

11

attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If

the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.

Disagreements regarding HRCT interpretation were resolved by a consensus between

both radiologists.

Review of histopathological findings

SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was

originally made in all cases on the basis of histological features evaluated by a lung

pathologist at our hospital, correlated with the clinical and radiological findings. All

SLB specimens were also reviewed by a second lung pathologist with 36 years of

experience. The histological classification of interstitial pneumonia was based on the

consensus statement criteria for idiopathic interstitial pneumonias,[16] and histological

patterns that could not be classified according to the criteria were categorised as

unclassified interstitial pneumonia.

Statistical analysis

All values are expressed as median (range) or number (%). The Mann-Whitney U test

was used for nonparametric comparisons involving continuous data, whereas Fisher's

12

exact test was used for comparing categorical data. Interobserver agreement on HRCT

pattern was analyzed using the κ statistic test. Survival was evaluated using the

Kaplan–Meier method and the log-rank test according to observation period. The

cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating

AE as the death variable according to AE free period. The 1-year AE incidence was

based on person year method and calculated by dividing the number of patients who

developed AE by the total of AE-free period (year) of all the patients. Cox hazards

analysis was used to determine significant variables associated with survival and AE

occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data

were analysed using commercially available software (JMP version 9.0.3a, SAS

Institute Inc, Cary, NC, USA).

RESULTS

Patient characteristics (Table 1)

   A total of 82 patients with RA-ILD were identified from medical records at

Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8

with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3

suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom

13

no initial HRCT images were available for review were also excluded. The remaining

51 patients with RA-ILD were included in this study.(Figure 1)

The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)

years and 62 (range, 31–83) years, respectively. The median observation period and

AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.

During the observation period, 11 patients (22%) developed AE. The median age at

the onset of AE was 72 (range, 60–86) years. There were no statistically significant

differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,

AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of

RA-ILD, and arterial oxygen pressure (PaO_2) at diagnosis of RA-ILD between the AE

and non-AE groups. Also there were no statistically significant differences in articular

disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE

occurrence (AE group).

In the AE group, seven of 11 patients (64%) died of respiratory failure caused by

initial AE during the observation period. In the non-AE group, two of 40 patients (5%)

died of respiratory failure. Regarding death caused by respiratory failure, there was a

statistically significant difference in the mortality rate between the AE and non-AE

groups (P=0.02).

14

Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51

patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in

2, glomerulonephritis in 1, rheumatoid nodule in 2). There were 3 (27%) patients with

extra-articular manifestations beyond ILD in AE group while 5 (13%) in non-AE group.

No significant difference in the incidence was observed between AE group and non-AE

group (P=0.26).

HRCT pattern (Table 1)

Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT.

HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%)

patients in the AE group demonstrated a UIP pattern. Interobserver agreement between

both radiologists was moderate (κ statistic test, κ = 0.44). The number of patients who

exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the

non-AE group.

When HRCT pattern was identified as a UIP pattern, the positive predictive value and

negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

Diagnostic accuracy of HRCT pattern for histopathological pattern (Table 2)

15

Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis

revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and

an unclassified interstitial pneumonia in 1. The diagnostic accuracy of HRCT pattern for

histopathological pattern was evaluated in 21 histopathologically confirmed patients.

The sensitivity, specificity, positive predictive value, and negative predictive value of

HRCT for histopathological evidence of UIP is 41.7%, 100%, 100% and 56.3%,

respectively.

Treatment for RA (Table 3)

Of the 51 patients, 37 (73%) had received treatment for RA at their final visit

(non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had

received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10

(20%) received MTX and 17 (33%) received other drugs. There were 6 (55%) patients

who had received MTX in AE group while 4 (10%) patients in non-AE group and

statistically significant difference was observed between the groups ($P = 0.001$).

No patients had received MTX before in AE group while 2 in non-AE group had

received MTX during observation period but discontinued prior to final visit. Thus,

there were 6 (55%) patients who had experienced MTX treatment during observation

16

period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX

dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE

group and 802mg (32-2496) in 6 patients among non-AE group. No statistically

significant difference was observed between two groups in cumulative MTX dose

(P=0.20).

Articular disease activities (RF and DAS28-CRP) were compared between patients

who had received MTX at the last visit or at the first AE occurrence, and those who had

not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) (P=0.25),

Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) (P=0.78),

respectively. There were no statistically significant differences in articular disease

activities.

AE incidence

The cumulative AE incidence in patients with RA-ILD is shown in Figure 2. The

5-year AE incidence was 11% [95% confidence interval (CI), 2–21%] in all patients,

33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT (UIP pattern group) and

3% (95% CI, 0–9%) in patients with a non-UIP pattern on HRCT (non-UIP pattern

group). The AE incidence was significantly higher in UIP pattern group than in

17

non-UIP pattern group (log-rank test, $P = 0.018$). The overall 1-year AE incidence was

2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the

non-UIP pattern group.

Univariate analysis (Table 4) revealed that older age at ILD diagnosis [hazard ratio

(HR), 1.11; 95% CI, 1.02–1.21; $P = 0.01$], UIP pattern on HRCT (HR, 1.95; 95% CI,

1.07–3.63; $P = 0.03$), and MTX usage (HR, 3.04; 95% CI, 1.62–6.02; $P = 0.001$) were

associated with the development of AE.

Survival

The overall survival of patients with RA-ILD and the survival according to HRCT

pattern subgroup are shown in Figure 3. The 5-year survival was 90% (95% CI,

81–98%) in all patients, 70% (95% CI, 44–94%) in the UIP pattern group and 97%

(95% CI, 92–100%) in the non-UIP pattern group. Survival was significantly poorer in

the UIP pattern group than in the non-UIP pattern group (log-rank test, $P = 0.04$).

The survival of AE group and non-AE group are shown in Figure 4., Significantly

worse survival was demonstrated in the AE group compared with the non-AE group

(log-rank test, $P = 0.001$).

Univariate analysis (Table 5) revealed that older age at ILD diagnosis (HR, 1.08;

18

95% CI, 0.99–1.17; $P = 0.057$) and UIP pattern on HRCT (HR, 1.74; 95% CI, 0.97–3.12; $P = 0.06$) showed a trend toward poor outcome, while AE (HR, 2.47; 95% CI, 1.39–4.56; $P = 0.003$) was significantly associated with poor survival.

DISCUSSION

To our knowledge, the present study is the first one focusing on the risk factors and prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern on HRCT, MTX usage, and older age at ILD diagnosis were associated with the development of AE. Furthermore, AE was a prognostic factor for poor survival.

The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[17, 18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 % for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, the 1-year AE incidence among patients with a UIP pattern on HRCT was 6.5% and cumulative incidence was significantly higher in UIP pattern group than in non-UIP pattern group. Therefore, a UIP pattern on HRCT was associated with the development of AE. In a previous report of small number of biopsy-proven cases, AE incidence among patients with RA-UIP was reported to be 11.1%, similar to that among patients with IPF.[4] The correlation

19

between pathological and radiological UIP patterns has been established in IPF, but not in RA-ILD.[19] In the present study, determination of a UIP pattern on HRCT exhibited high specificity and positive predictive values for the detection of pathological UIP pattern. Therefore, a typical UIP pattern on HRCT was assumed to be highly suggestive of pathological UIP pattern in patients with RA-ILD as well as IPF.[15, 19] Collectively, these results suggest that AE incidence in a subgroup with pathological UIP pattern or a UIP pattern on HRCT may be higher than that in other patterns..

The present study also identified MTX usage was associated with the development of AE. MTX is widely used to treat RA, while its toxicity affects the pulmonary system. Diagnostic criteria for MTX-associated pneumonitis (MTX-pneumonitis) have been proposed previously.[20] However, the specificity of the criteria has not been fully examined yet. MTX-pneumonitis typically occurs with acute/subacute onset early in the course of MTX treatment,[20-23] in particular, mostly within the first year[24] and often presents a hypersensitive pneumonitis pattern. Patients with MTX-pneumonitis generally respond to discontinuation of MTX or corticosteroid treatment and have a favorable prognosis.[20-23] In the present study, 6 of 11 patients with AE had received MTX, and 5 of the 6 patients had been treated for 3 or more years. The remaining patient had been treated for 1 year. In all 6 patients, their respiratory conditions

20

progressively deteriorated despite discontinuation of MTX, and they poorly responded

to high-dose corticosteroid. Consequently, on the basis of inconsistency in terms of

MTX treatment duration and clinical features, we diagnosed these patients with AE of

RA-ILD.

Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown;

however, several reports have suggested that AE may be a distinct manifestation of the

primary disease process, a distinct condition associated with undiagnosed infection, or a

subsequent acceleration of a fibroproliferative process caused by acute direct stress to

the lung.[1] In the present study, DAS28-CRP in all patients with AE showed low

disease activity or remission at the time of AE occurrence, and no significant difference

in articular disease activities was observed between AE group and non-AE group or

regardless of MTX treatment; therefore, RA activity may not be related to AE

occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates

the fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk

factor for RA-ILD progression.[12] For RA-ILD, MTX may be associated not only with

newly developing drug-induced pneumonitis but also with deterioration of pre-existing

ILD, including AE.

The present study found that patients with a UIP pattern on HRCT had significantly

21

poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic

factor for poor outcome. AE has a serious impact on the survival of patients with

IPF,[18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these

reports, the present study revealed that seven (64%) of 11 patients with AE died of

respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE

group was significantly poorer than that in the non-AE group. Therefore, AE is

suggested to be a predictor of poor prognosis in patients with RA-ILD as well as

patients with IPF.

Other prognostic factors in RA-ILD have been reported, including pathological

UIP,[25-29] UIP pattern on HRCT,[30] and age at RA-ILD onset.[31] In the present

study, pathological UIP could not be identified as prognostic factors because the number

of biopsy-proven cases were small. However, we observed similar results regarding UIP

pattern on HRCT and age at RA-ILD onset.

In our study, the average time between age at onset of RA and that of RA-ILD was

relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported

that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In

another point of view, since the current authors' institution is regional referral center for

interstitial lung disease, referral bias might have increased the proportion of patients

22

with early-stage ILD, leading above results.

This study had several limitations. First, given its retrospective study design, it is subject to several possible biases. For instance, selection and recall bias may exist. Second, because of the relatively small sample size, it may be difficult to determine the precise incidence of AE and the number of event (AE occurrence or death) was too small to perform multivariate analysis. In this analysis, the incidence of extra-articular manifestations beyond ILD and the proportion of current/former smokers in AE group were higher than those in non-AE group (27% vs. 13% and 82% vs. 55%, respectively), with no statistically significant differences. Such differences might be statistically significant in a larger study. Therefore, larger studies are necessary to confirm our results. Third, because the presence of a UIP pattern on HRCT had low sensitivity and negative predictive value for the detection of pathologic UIP, it was likely that some patients with a non-UIP pattern on HRCT may have had pathological UIP. HRCT criteria used in our study do not aim to detect pathological UIP but to clinically diagnose IPF and to exclude alternative diagnosis.[15] The frequency of honeycombing on HRCT differs between RA-ILD and IPF, and some ILDs by other causes including RA-ILD have some of findings inconsistent with UIP. Therefore, HRCT pattern in RA-ILD may be more frequently interpreted as non-UIP pattern than that in IPF. In our

study, 2 of 5 patients with histopathological UIP in the absence of a UIP pattern on

HRCT develop AE. Thus, SLB may have to be considered for these patients to make

pathological diagnosis and to predict AE. Finally, RA includes a variety of

manifestations. Therefore, other comorbidities may have affected the results.

In conclusion, older age at ILD diagnosis, UIP pattern on HRCT and MTX usage are

associated with the development of AE in patients with RA-ILD. Furthermore, the

mortality associated with AE is high and AE is prognostic factor for poor outcome.

Larger prospective studies investigating acute exacerbations in RA-ILD are indicated.

ACKNOWLEDGMENT

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the

integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed

acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and

analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S.,

and K.C. revised the paper.

All authors approved the paper.

25

Competing interest:

All authors do not have any personal or financial support or involvement with

organization(s) that have financial interest in the subject matter, or any competing

interest.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this

study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images.

Copyright:

I *[Yutaro Nakamura*] the Corresponding Author of this article contained within the

original manuscript which includes any diagrams & photographs, other illustrative

material, video, film or any other material howsoever submitted by the Contributor(s) at

26

any time and related to the Contribution ("the Contribution") have the right to grant on

behalf of all authors and do grant on behalf of all authors, a licence to the BMJ

Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be

published in BMJ Open and any other BMJ Group products and to exploit all subsidiary

rights, as set out in the licence

Data sharing

No unpublished data from the study are available.

27

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.

2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.

3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.

4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.

5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.

6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.

7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722–7.

8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

28

their impact on outcome. Rheumatology (Oxford). 2013;52:99-110.

9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. *Ann Rheum Dis.* 2003;62:897–900.

10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. *Thorax.* 2001;56:622–7.

11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. *Am J Respir Crit Care Med.* 1997;156:528–35.

12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. *Arch Intern Med.* 2008;168:159–66.

13. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. *J Rheumatol.* 2008;35:1513–21.

14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988;31:315-24.

15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on

    Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:

    idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and

    management. *Am J Respir Crit Care Med.* 2011;183:788-824.

16. American Thoracic Society/European Respiratory Society International

    Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.

    Am J Respir Crit Care Med. 2002;165:277-304.

17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary

    fibrosis. *Chest.* 2007;132:1652-8.

18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary

    fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.

19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung

    disease: the relevance of histopathologic and radiographic pattern. *Chest.*

    2009;136:1397-405.

20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,

    and histopathologic features of methotrexate-associated lung injury in patients with

    rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.*

    1997;40:1829-37.

30

21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.

22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.* 2009;68:1100-4.

23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. *Eur Respir J.* 2000;15:373-81.

24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.

25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.

26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am Rev Respir Dis.* 1985;131:770-7.

27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.

28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern

as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.

29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia:

    idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care*

    Med. 2007;175:705-11.

30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in

    rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.*

    2010;35:1322-8.

31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study).

    Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an

    inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.

Table 1 Clinical characteristics

Characteristics	Total	Non-AE group[#]	AE group[¶]	P value[+]
	N = 51 (100)	N = 40 (78)	N = 11 (22)	
Median age, years (range)				
at RA diagnosis	61 (28-82)	60 (28-81)	65 (42-82)	0.15
at ILD diagnosis	62 (31-83)	62 (31-83)	69 (58-83)	0.15
at AE onset			72 (60-86)	
Sex Male, n (%)	29 (57)	23 (58)	6 (55)	0.86
Observation period, years (range)	8.5 (1-17)	9 (1-17)	6.4 (2-14)	0.45
AE-free period, years (range)	7(1-17)	9 (1-17)	6 (2-14)	0.19
Smoking habit, n (%)				
Never	20 (39)	18 (45)	2 (18)	
Former	24 (47)	16 (40)	8 (73)	0.15
Current	7 (14)	6 (15)	1 (9)	
RF, IU/mL (range)[*]	197 (6-2666)	189 (6-2666)	205 (39-2530)	0.47
DAS28-CRP, score (range)[*]	1.95(1.02-5.13)	2.53(1.02-5.13)	1.82(1.47-2.3)	0.62
PaO_2, torr (range)	82.4 (67-109)	81 (67-102)	85.8 (74-109)	0.19
%FVC, % (range)	91.1 (50.6-130)	87.5 (51-130)	95 (60-125)	0.38
HRCT pattern, n (%)				
UIP pattern	14 (27)	8 (20)	6 (55)	0.02[§]
non-UIP pattern	37 (73)	32 (80)	5 (45)	
Death during observation period, n (%)				
caused by respiratory failure	9 (18)	2 (5)	7 (64)	0.02[§]
caused by other diseases	3 (6)	3 (8)	0 (0)	

Data are presented as n (%), median (range). AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

[+]Non-AE group vs AE group

[§]$p < 0.05$

[*]at the first AE occurrence (AE group) or the last visit (non-AE group).

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

33

In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding and 2 of unknown causes.

34

Table 2 Diagnostic accuracy of HRCT pattern for histopathological pattern in 21 histopathologically confirmed patients.

	Histopathological pattern		Total
	UIP	Other pattern	
UIP pattern on HRCT	5	0	5
non-UIP pattern on HRCT	7	9	16
Total	12	9	21

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

The sensitivity, specificity, positive predictive value, and negative predictive value of HRCT for histopathological evidence of UIP is 41.7%, 100%, 100% and 56.3%, respectively.

35

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

	Total	non-AE group[+]	AE group[§]	P value
	N = 51	N = 40 (78%)	N = 11 (22%)	
Treatment, yes	37 (73)	27(68)	10 (91)	0.12
Corticosteroid	29 (57)	22 (55)	7 (64)	0.61
Immunosuppressant except for MTX	17 (33)	14 (35)	3 (27)	0.63
MTX	10 (20)	4 (10)	6 (55)	0.001[*]
Other drugs	17 (33)	13 (33)	4 (36)	0.81

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cycrophosphaminde (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

[+] Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

[*] $p < 0.05$

36

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	1.03	0.97-1.10	0.35
Age at ILD diagnosis	1.11	1.02-1.21	0.01[+]
Sex, male	0.90	0.49-1.69	0.73
Smoking habit, yes	1.60	0.81-4.10	0.19
UIP pattern on HRCT, yes	1.95	1.07-3.63	0.03[+]
PaO_2 at ILD diagnosis	1.05	0.98-1.12	0.14
%FVC at ILD diagnosis	1.02	0.99-1.06	0.24
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	0.97	0.53-1.92	0.94
Immunosuppressant except for MTX	0.76	0.35-1.41	0.39
MTX	3.04	1.62-6.02	0.001[+]
Other drugs	0.98	0.50-1.80	0.96

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT,

high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital

capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence

interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	0.98	0.93-1.04	0.48
Age at ILD diagnosis	1.08	0.99-1.17	0.057
Sex, male	1.14	0.63-2.22	0.67
Smoking habit, yes	1.70	0.87-4.35	0.13
UIP pattern on HRCT, yes	1.74	0.97-3.12	0.06
PaO_2 at ILD diagnosis	1.05	0.98-1.11	0.15
%FVC at ILD diagnosis	1.01	0.98-1.04	0.55
AE during observation period, yes	2.47	1.39-4.56	0.003[+]
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	1.23	0.67-2.65	0.52
Immunosuppressant except for MTX	0.69	0.32-1.27	0.25
MTX	1.44	0.67-2.68	0.31
Other drugs	0.76	0.36-1.41	0.40

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were

excluded, and 51 patients with chronic course of RA-ILD were included. During

observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE

compared with non-UIP pattern on HRCT (log-rank p=0.018).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP,

usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with

those with non-UIP pattern on HRCT (log-rank p=0.04).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly

worse survival compared with those who did not (non-AE group) (log-rank *p*=0.001).

AE, acute exacerbation.

FIGURE 1.

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were excluded, and 51 patients with chronic course of RA-ILD were included. During observation period, 11 patients developed AE. RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.
80x160mm (300 x 300 DPI)

FIGURE 2.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE compared with non-UIP pattern on HRCT (log-rank p=0.018).
AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
80x80mm (300 x 300 DPI)

FIGURE 3.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with those with non-UIP pattern on HRCT (log-rank p=0.04).
UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.
80x80mm (300 x 300 DPI)

FIGURE 4.

Figure 4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly worse survival compared with those who did not (non-AE group) (log-rank p=0.001).
AE, acute exacerbation.
80x80mm (300 x 300 DPI)

Title: Acute exacerbation in rheumatoid arthritis associated interstitial lung disease

Authors:

Hironao Hozumi, M.D., Ph.D.[1]

Yutaro Nakamura, M.D., Ph.D.[1]

Takeshi Johkoh, M.D., Ph.D.[2]

Hiromitsu Sumikawa, M.D., Ph.D.[3]

Thomas V. Colby, M.D.[4]

Masato Kono, M.D, Ph.D.[1]

Dai Hashimoto, M.D., Ph.D.[1]

Noriyuki Enomoto, M.D., Ph.D.[1]

Tomoyuki Fujisawa, M.D., Ph.D.[1]

Naoki Inui, M.D., Ph.D.[1]

Takafumi Suda, M.D., Ph.D.[1]

Kingo Chida, M.D., Ph.D.[1]

Affiliations:

[1]Second division, Department of Internal Medicine, Hamamatsu University School of

1

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

[2]Department of Radiology, Kinki Central Hospital of Mutual Aid Association of Public

School Teachers, 3-1 Kurumazuka, Itami-city, Hyogo 664-8533, Japan

[3]Diagnostic and Interventional Radiology, Osaka University Graduate School of

Medicine, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan

[4]Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, 13400 East

Shea Boulevard Scottsdale, AZ 85259, USA

Corresponding author:

Yutaro Nakamura, M.D., Ph.D.

Second division, Department of Internal Medicine, Hamamatsu University School of

Medicine, 1-20-1 Handayama Higashiku, Hamamatsu 431-3192, Japan

Tel: 81-53-435-2263, Fax: 81-53-435-2354

E-mail address: nakayuta@hama-med.ac.jp

2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Word count paper: 3494382

Word count abstract: 27980

3

ABSTRACT

Background   Acute exacerbation (AE) in idiopathic pulmonary fibrosis is
characterised by acute deterioration of respiratory status and the mortality is high.
Recently, AE was reported in patients with other interstitial lung diseases, especially
rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Objectives   To investigate the risk factors and prognosis associated with AE in
patients with RA-ILD.

Design   A retrospective case-control study.

Setting   A single academic hospital.

Participants   51 consecutive patients diagnosed with RA-ILD between 1995 and 2012.
All patients fulfilled the diagnostic criteria of the American College of Rheumatology
for RA. ILD was diagnosed on the basis of clinical presentation, pulmonary function
tests, high resolution computed tomography (HRCT) findings, and lung biopsy findings.

Main outcome measures   Overall survival and cumulative AE incidence were
analysed using Kaplan–Meier method. Cox hazards analysis was used to determine
significant variables associated with AE occurrence and survival status.

Results   A total of 11 patients (22%) developed AE, with an overall 1-year incidence
of 2.8%. Univariate analysis revealed that higher older age at ILD diagnosis [hazard

4

ratio (HR), 1.11; 95% confidence interval (CI), 1.02–1.21; *P* = 0.01], usual interstitial pneumonia (UIP) pattern on HRCT (HR, 1.95; 95% CI, 1.07–3.63; *P* = 0.03) and ~~treatment with~~ methotrexate usage (HR, 3.04; 95% CI, 1.62–6.02; *P* = 0.001) were ~~risk factors for~~ associated with AE. Of 11 patients who developed AE during observation period, seven (64%) died of initial AE. In survival, AE was a prognostic factor for poor outcome (HR, 2.47; 95% CI, 1.39–4.56; *P* = 0.003).

Conclusions   In patients with RA-ILD, old~~high~~er age at ILD diagnosis, UIP pattern on HRCT and ~~treatment with~~ methotrexate usage are ~~risk factors~~associated with ~~for~~ the development of AE. Furthermore, AE has a serious impact on their survival.

5

Article focus;

Acute exacerbation occurs not only in patients with idiopathic pulmonary fibrosis

(IPF) but also in patients with rheumatoid arthritis associated interstitial lung disease

(RA-ILD).

What is the risk factor for AE and does AE impact on prognosis in patients with

RA-ILD?

Key messages;

In patients with RA-ILD, ~~higher~~ older age at ILD diagnosis, UIP pattern on HRCT~~,~~

and ~~treatment with~~ methotrexate usage are ~~risk factors for~~ associated with AE

occurrence.

In patients with RA-ILD, AE is associated with poor prognosis.

Strengths and limitations of this study;

AE has a serious impact on the survival of patients with RA-ILD.

Given its retrospective study design, it is subject to several possible biases. Therefore,

prospective studies are necessary to confirm our results.

6

INTRODUCTION

Acute exacerbation (AE) is a recently established and an increasingly recognised occurrence in idiopathic pulmonary fibrosis (IPF).[1] AE is characterised by acute deterioration in respiratory status, with newly developed bilateral ground-glass opacities and/or consolidations on chest radiographs or computed tomography scans. It should be in the absence of other alternative causes such as infection, left heart failure, pulmonary embolism, orand an identifiable cause of acute lung injury. AE reportedly occurs not only in patients with IPF but also in patients with other interstitial lung diseases (ILDs), including idiopathic nonspecific interstitial pneumonia (NSIP), collagen vascular disease-associated ILDs (CVD-ILDs) and other forms of ILD.[2-4] The in-hospital mortality associated with AE in patients with CVD-ILD was demonstrated to be as high as that in patients with IPF,[1-4] suggesting that AE may be associated with poor prognosis in patients with CVD-ILD.

Rheumatoid arthritis (RA) is a chronic, systemic, autoimmune disorder of unknown etiology that primarily involves joints.[5] ILD is one of common extra-articular manifestations.[6, 7] The reported prevalence is variable (1–58%) and depends on the detection and diagnostic method, or the selected population.[8-13] We and Park *et al* previously reported that RA-associated ILD (RA-ILD) was the most common

7

CVD-ILD associated with AE.[3, 4] However the risk factors and prognosis associated

with AE in patients with RA-ILD are not clarified.

In the present study, we attempted to elucidate the cumulative incidence of AE, its

risk factors, and prognostic factors in patients with RA-ILD.

MATERIALS AND METHODS

Subjects

Institutional review board in Hamamatsu University School of Medicine approved

this study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images. We

retrospectively reviewed 51 consecutive patients diagnosed with RA-ILD between 1995

and 2012 at Hamamatsu University Hospital in Japan. All patients fulfilled the

diagnostic criteria of the American College of Rheumatology for RA.[14] Patients with

other coexisting CVD were excluded. In addition, because our aim was to investigate

the features of AE among patients with a chronic course of RA-ILD, patients with no

evidence of chronic ILD were also excluded. Chronic ILD was defined as the ILD

which had been stable for over 3 months.

ILD was diagnosed on the basis of clinical presentation, pulmonary function tests,

8

high resolution computed tomography (HRCT) findings, and lung biopsy findings.

HRCT findings such as bilateral areas with ground-glass attenuation, reticular opacities

and honeycomb patterns were interpreted and defined as ILD by a consensus between

radiologists and pulmonologists. All cases underwent transbronchial lung biopsy and

bronchoalveolar lavage, and 21 (41%) cases underwent surgical lung biopsy (SLB) to

definitively diagnose ILD or rule out other diseases. The patients with environmental

exposures, suspected of drug induced pneumonia (ILD developed within 1 year after

initiation of new drug), or with other known causes of ILD were excluded after

considering exposure history and the findings of appropriate tests and histopathological

examinations.

Acute exacerbation (AE)

AE was defined using recently proposed criteria[1] that were slightly modified for

adaptation to RA-ILD: previous diagnosis of RA-ILD, unexplained worsening or

development of dyspnea within 30 days of onset, new bilateral ground-glass

abnormalities and/or consolidation superimposed on a reticular or honeycomb pattern

on HRCT, no evidence of pulmonary infection on negative respiratory culture,

including endotracheal aspirate or bronchoalveolar lavage, and serological test results

9

for respiratory pathogens, and exclusion of alternative causes such as left heart failure,

pulmonary embolism, ~~and~~ or an identifiable cause of ~~acute~~ lung injury. Patients with AE

were required to meet all five criteria. In our institution, cultures of sputum, blood, urine,

and bronchoalveolar lavage fluid, and serological tests examined for mycobacteria,

fungi, bacteria, and some viruses were routinely performed. Echocardiography and, if

necessary, CT scanning with intravenous contrast were performed to rule out left heart

failure or pulmonary thromboembolism. The patients who developed acute pneumonitis

within 1 year after initiation of drug for RA were excluded because drug-induced

pneumonitis was not completely ruled out. Patients who did or did not develop AE

during the observation period were classified into the AE and non-AE groups,

respectively.

Data collection

All clinical and laboratory data were collected from medical records. The observation

period was calculated from the date of diagnosis of RA-ILD to the last visit. The

AE-free period was defined as the time elapsed between the date of RA-ILD diagnosis

and the first AE occurrence (AE group) or the last visit (non-AE group).

10

Review of radiographic findings

HRCT images taken at the time of RA-ILD diagnosis were reviewed. These images comprised 1 to 2.5-mm collimation sections at 10 mm intervals. They were reconstructed by a high spatial frequency algorithm, and were displayed at window settings appropriate for viewing the lung parenchyma (window level, -600 to -800 Hounsfield units; window width, 1200 to 2000 Hounsfield units). HRCT images were randomised and reviewed independently by two expert chest radiologists (with 23 and 12 years of experience) who were unaware of the related clinical information. Interobserver agreement was classified as follows: poor ($\kappa = 0–0.20$), fair ($\kappa = 0.21–0.40$), moderate ($\kappa = 0.41–0.60$), good ($\kappa = 0.61–0.80$) and excellent ($\kappa = 0.81-1.00$).

RA-ILD on HRCT was classified as a usual interstitial pneumonia (UIP) pattern or a non-UIP pattern according to recent guideline with slight modification.[15] Briefly, a UIP pattern on HRCT was characterised by subpleural and basal predominance, reticular abnormalities, honeycombing with or without traction bronchiectasis and the absence of features listed as inconsistent with a UIP pattern, including upper or mid-lung predominance, peribronchovascular predominance, extensive ground glass abnormalities, profuse micronodules, discrete cysts, diffuse mosaic

11

attenuation/air-trapping and consolidation in bronchopulmonary segment(s)/lobe(s). If

the HRCT pattern did not meet the criteria, it was interpreted as a non-UIP pattern.

Disagreements regarding HRCT interpretation were resolved by a consensus between

both radiologists.

Review of histopathological findings

SLB specimens were obtained from at least two sites. A diagnosis of RA-ILD was

originally made in all cases on the basis of histological features evaluated by a lung

pathologist at our hospital, correlated with the clinical and radiological findings. All

SLB specimens were also reviewed by a second lung pathologist with 36 years of

experience. The histological classification of interstitial pneumonia was based on the

consensus statement criteria for idiopathic interstitial pneumonias,[16] and histological

patterns that could not be classified according to the criteria were categorised as

unclassified interstitial pneumonia.

Statistical analysis

All values are expressed as median (range) or number (%). The Mann-Whitney U test

was used for nonparametric comparisons involving continuous data, whereas Fisher's

12

exact test was used for comparing categorical data. Interobserver agreement on HRCT

pattern was analyzed using the κ statistic test. Survival was evaluated using the

Kaplan–Meier method and the log-rank test according to observation period. The

cumulative AE incidence was obtained from a Kaplan–Meier survival curve by treating

AE as the death variable according to AE free period. The 1-year AE incidence was

based on person year method and calculated by dividing the number of patients who

developed AE by the total of AE-free period (year) of all the patients. Cox hazards

analysis was used to determine significant variables associated with survival and AE

occurrence. In all analyses, $P < 0.05$ was considered statistically significant. All data

were analysed using commercially available software (JMP version 9.0.3a, SAS

Institute Inc, Cary, NC, USA).

RESULTS

Patient characteristics (Table 1)

   A total of 82 patients with RA-ILD were identified from medical records at

Hamamatsu University Hospital. From these, 11 patients with other coexisting CVDs, 8

with no evidence of chronic ILD and an initial acute/subacute course of ILD, and 3

suspected of drug-induced pneumonitis were excluded. In addition, 9 patients for whom

13

no initial HRCT images were available for review were also excluded. The remaining

51 patients with RA-ILD were included in this study.(Figure 1)

The median age at onset of RA and diagnosis of RA-ILD was 61 (range, 28–82)

years and 62 (range, 31–83) years, respectively. The median observation period and

AE-free period was 8.5 (range, 1–17) years and 7 (range, 1–17) years, respectively.

During the observation period, 11 patients (22%) developed AE. The median age at

the onset of AE was 72 (range, 60–86) years. There were no statistically significant

differences in age at onset of RA, age at diagnosis of RA-ILD, sex, observation period,

AE-free period, smoking habits, predicted forced vital capacity (%FVC) at diagnosis of

RA-ILD, and arterial oxygen pressure (PaO_2) at diagnosis of RA-ILD between the AE

and non-AE groups. Also there were no statistically significant differences in articular

disease activities (RF and DAS28-CRP) at the last visit (non-AE group) or the first AE

occurrence (AE group).

In the AE group, seven of 11 patients (64%) died of <u>respiratory failure caused by</u>

<u>initial AE</u> during the observation period. In the non-AE group, 2 <u>two</u> of 40 patients

(5%) died of respiratory failure. <u>Regarding death caused by respiratory failure, t</u>There

was a statistically significant difference in the mortality rate between the AE and

non-AE groups <u>(P=0.02)</u>.

14

Extra-articular manifestations except for ILD had been observed in 8 (16%) of 51 patients (pericarditis in 2 patients, pleuritis in 1, neuropathy in 2, cutaneous vasculitis in 2, glomerulonephritis in 1, rheumatoid nodule in 2). There ~~was~~ were 3 (27%) patients with extra-articular manifestations beyond ILD in AE group while 5 (13%) in non-AE group. N~~n~~o significant difference in the incidence was observed between AE group and non-AE group (~~27% vs. 13%,~~ P=0.26).

HRCT pattern (Table 1)

Of the 51 patients with RA-ILD, 14 (27%) exhibited the UIP pattern on HRCT. HRCT images of eight of 40 patients (20%) in the non-AE group and six of 11 (55%) patients in the AE group demonstrated a UIP pattern. Interobserver agreement between both radiologists was moderate (κ statistic test, κ = 0.44). The number of patients who exhibited a UIP pattern on HRCT was significantly higher in the AE group than in the non-AE group.

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

Diagnostic accuracy of HRCT pattern for histopathological pattern (Table 2)

15

Among the 51 patients, 21 (41%) underwent SLB. Histopathological analysis

revealed a UIP in 12 patients, NSIP in 7, desquamative interstitial pneumonia in 1 and

an unclassified interstitial pneumonia in 1. The diagnostic accuracy of HRCT pattern for

histopathological pattern was evaluated in 21 histopathologically confirmed patients.

~~When the pattern was identified as a UIP pattern on HRCT, t~~The sensitivity, specificity,

positive predictive value, and negative predictive value of HRCT for ~~detecting~~

histopathological evidence of UIP ~~was~~ is 41.7%, 100%, 100% and 56.3%, respectively.

Treatment for RA (Table 3)

Of the 51 patients, 37 (73%) had received treatment for RA at their final visit

(non-AE group) or at AE onset (AE group). Specifically, 29 patients (57%) had

received corticosteroids, 17 (33%) received immunosuppressants except for MTX, 10

(20%) received MTX and 17 (33%) received other drugs. There were 6 (55%) patients

who had received MTX in AE group while 4 (10%) patients in non-AE group and

statistically significant difference was observed between the groups ($P = 0.001$).

No patients had received MTX before in AE group while 2 in non-AE group had

received MTX during observation period but discontinued prior to final visit. Thus,

there were 6 (55%) patients who had experienced MTX treatment during observation

16

period in AE group while 6 (15%) patients in non-AE group. Median cumulative MTX

dose were 1952mg (384-3872) in 6 patients who had experienced MTX among AE

group and 802mg (32-2496) in 6 patients among non-AE group. No statistically

significant difference was observed between two groups in cumulative MTX dose

(P=0.20).

Articular disease activities (RF and DAS28-CRP) were compared between patients

who had received MTX at the last visit or at the first AE occurrence, and those who had

not. Median RF (range) were 112 IU/mL (16-334) and 284 IU/mL (6-2666) (P=0.25),

Median DAS28-CRP (range) were 1.94 (1.02-3.87) and 1.97 (1.02-5.13) (P=0.78),

respectively. There were no statistically significant differences in articular disease

activities.

AE incidence

The cumulative AE incidence in patients with RA-ILD is shown in Figure 2. The

5-year AE incidence was 11% [95% confidence interval (CI), 2–21%] in all patients,

33% (95% CI, 7–60%) in patients with a UIP pattern on HRCT (UIP pattern group) and

3% (95% CI, 0–9%) in patients with a non-UIP pattern on HRCT (non-UIP pattern

group). The AE incidence was significantly higher in UIP pattern group than in

17

non-UIP pattern group (log-rank test, $P = 0.018$). The overall 1-year AE incidence was

2.8%. The 1-year AE incidence was 6.5% in the UIP pattern group and 1.7 % in the

non-UIP pattern group.

Univariate analysis (Table 4) revealed that ~~higher~~ older age at ILD diagnosis [hazard

ratio (HR), 1.11; 95% CI, 1.02–1.21; $P = 0.01$], UIP pattern on HRCT (HR, 1.95; 95%

CI, 1.07–3.63; $P = 0.03$), and ~~treatment with~~ MTX usage (HR, 3.04; 95% CI, 1.62–6.02;

$P = 0.001$) were associated with the development of AE.~~significant risk factors for AE~~

~~occurrence.~~

Survival

The overall survival of patients with RA-ILD and the survival according to HRCT

pattern subgroup are~~is~~ shown in Figure 3.

The 5-year survival was 90% (95% CI, 81–98%) in all patients, 70% (95% CI, 44–94%)

in the UIP pattern group and 97% (95% CI, 92–100%) in the non-UIP pattern group.

Survival was significantly poorer in the UIP pattern group than in the non-UIP pattern

group (log-rank test, $P = 0.04$).

The survival of AE group and non-AE group are shown in Figure 4.~~In addition~~,

S~~si~~gnificantly worse survival was demonstrated in the AE group compared with the

18

non-AE group (~~Figure 4,~~ log-rank test, P = 0.001).

Univariate analysis (Table 5) revealed that ~~higher~~ older age at ILD diagnosis (HR, 1.08; 95% CI, 0.99–1.17; P = 0.057) and UIP pattern on HRCT (HR, 1.74; 95% CI, 0.97–3.12; P = 0.06) showed a trend toward poor outcome, while AE (HR, 2.47; 95% CI, 1.39–4.56; P = 0.003) was significantly associated with poor survival.

DISCUSSION

To our knowledge, the present study is the first one focusing on the risk factors and prognosis associated with AE in patients with RA-ILD. The overall 1-year AE incidence was 2.8% among the RA-ILD patients. Univariate analysis identified that a UIP pattern on HRCT, MTX ~~treatment~~ usage, and ~~higher~~ older age at ILD diagnosis were associated with the development of ~~significant risk factors for~~ AE. Furthermore, AE was a prognostic factor for poor survival.

The 1-year AE incidence among patients with IPF has been reported to be 5-19%,[17, 18] whereas that among patients with other ILDs was 4.2% for idiopathic NSIP, 3.3 % for CVD-ILD and 5.6 % for CVD-UIP.[4] In the present study, the 1-year AE incidence among patients with a UIP pattern on HRCT was 6.5% and cumulative incidence was significantly higher in UIP pattern group than in non-UIP pattern group.

19

~~Furthermore~~Therefore, a UIP pattern on HRCT was associated with the development of ~~a risk factor for~~ AE. In a previous report of small number of biopsy-proven cases, AE

incidence among patients with RA-UIP was reported to be 11.1%, similar to that among

patients with IPF.[4] The correlation between pathological and radiological UIP patterns

has been established in IPF, but not in RA-ILD.[19] In the present study, determination

of a UIP pattern on HRCT exhibited high specificity and positive predictive values for

the detection of pathological UIP pattern. Therefore, a typical UIP pattern on HRCT was

assumed to be highly suggestive of pathological UIP pattern in patients with RA-ILD as

well as IPF.[15, 19] Collectively, these results suggest that AE incidence in a subgroup

with pathological UIP pattern or a UIP pattern on HRCT may be higher than that in

other patterns..

The present study also identified MTX ~~treatment~~ usage was associated with the

development of ~~as a risk factor for~~ AE. MTX is widely used to treat RA, while its

toxicity affects the pulmonary system. Diagnostic criteria for MTX-associated

pneumonitis (MTX-pneumonitis) have been proposed previously.[20] However, the

specificity of the criteria has not been fully examined yet. MTX-pneumonitis typically

occurs with acute/subacute onset early in the course of MTX treatment,[20-23] in

particular, mostly within the first year[24] and often presents a hypersensitive

20

pneumonitis pattern. Patients with MTX-pneumonitis generally respond to discontinuation of MTX or corticosteroid treatment and have a favorable prognosis.[20-23] In the present study, 6 of 11 patients with AE had received MTX, and 5 of the 6 patients had been treated for 3 or more years. The remaining patient had been treated for 1 year. In all 6 patients, their respiratory conditions progressively deteriorated despite discontinuation of MTX, and they poorly responded to high-dose corticosteroid. Consequently, on the basis of inconsistency in terms of MTX treatment duration and clinical features, we diagnosed these patients with AE of RA-ILD.

Similar to AE in patients with IPF, the etiology of AE in RA-ILD is unknown; however, several reports have suggested that AE may be a distinct manifestation of the primary disease process, a distinct condition associated with undiagnosed infection, or a subsequent acceleration of a fibroproliferative process caused by acute direct stress to the lung.[1] In the present study, DAS28-CRP in all patients with AE showed low disease activity or remission at the time of AE occurrence, and no significant difference in articular disease activities was observed between AE group and non-AE group or regardless of MTX treatment; therefore, RA activity may not be related to AE occurrence, a finding similar to that of a previous study.[4] MTX possibly accelerates the fibroproliferative process of RA-ILD. It was reported that MTX treatment was a risk

21

factor for RA-ILD progression.[12] For RA-ILD, MTX may be associated not only with

newly developing drug-induced pneumonitis but also with deterioration of pre-existing

ILD, including AE.

The present study found that patients with a UIP pattern on HRCT had significantly

poorer survival than those with a non-UIP pattern. In addition, AE was a prognostic

factor for poor outcome. AE has a serious impact on the survival of patients with

IPF,[18] and it may also affect the prognosis in other ILDs.[3, 4] Consistent with these

reports, the present study revealed that seven (64%) of 11 patients with AE died of

respiratory failure, giving rise to high in-hospital mortality, and that survival in the AE

group was significantly poorer than that in the non-AE group. Therefore, AE is

suggested to be a predictor of poor prognosis in patients with RA-ILD as well as

patients with IPF.

Other prognostic factors in RA-ILD have been reported, including pathological

UIP,[25-29] UIP pattern on HRCT,[30] and age at RA-ILD onset.[31] In the present

study, pathological UIP could not be identified as prognostic factors because the number

of biopsy-proven cases were small. However, we observed similar results regarding UIP

pattern on HRCT and age at RA-ILD onset.

In our study, the average time between age at onset of RA and that of RA-ILD was

22

relatively shorter than some previous reports.[7, 8] However, Gabbay et al [11] reported that nearly 60 % of the patients have interstitial lung disease in recent onset RA. In another point of view, since the current authors' institution is regional referral center for interstitial lung disease, referral bias might have increased the proportion of patients with early-stage ILD, leading above results.

This study had several limitations. First, given its retrospective study design, it is subject to several possible biases. For instance, selection and recall bias may exist. Second, because of the relatively small sample size, it may be difficult to determine the precise incidence of AE and the number of event (AE occurrence or death) was too small to perform multivariate analysis. In this analysis, the incidence of extra-articular manifestations beyond ILD and the proportion of current/former smokers in AE group were higher than those in non-AE group (27% vs. 13% and 82% vs. 55%, respectively), with no statistically significant differences. Such differences might be statistically significant in a larger study. Therefore, larger studies are necessary to confirm our results. Third, because the presence of a UIP pattern on HRCT had low sensitivity and negative predictive value for the detection of pathologic UIP, it was likely that some patients with a non-UIP pattern on HRCT may have had pathological UIP. HRCT criteria used in our study do not aim to detect pathological UIP but to clinically

23

diagnose IPF and to exclude alternative diagnosis.[15] The frequency of honeycombing

on HRCT differs between RA-ILD and IPF, and some ILDs by other causes including

RA-ILD have some of findings inconsistent with UIP. Therefore, HRCT pattern in

RA-ILD may be more frequently interpreted as non-UIP pattern than that in IPF. In our

study, 2 of 5 patients with histopathological UIP in the absence of a UIP pattern on

HRCT develop AE. Thus, SLB may have to be considered for these patients to make

pathological diagnosis and to predict AE. Finally, RA includes a variety of

manifestations. Therefore, other comorbidities may have affected the results.

In conclusion, ~~higher~~ older age at ILD diagnosis, UIP pattern on HRCT and ~~treatment with~~ MTX usage are associated with the development of~~risk factors for~~ AE ~~occurrence~~

in patients with RA-ILD. Furthermore, the mortality associated with AE is high and AE

is prognostic factor for poor outcome. Larger prospective studies investigating acute

exacerbations in RA-ILD are indicated.

24

Guarantor statement:

Y.N. had full access to all the data in present study, and takes responsibility for the

integrity of the data and the accuracy of the data analysis.

Authorship:

H.H., Y.N., T.S., and K.C. designed research; H.H., D.H., T.F., and N.I. contributed

acquisition of data; H.H., Y.N., T.J., H.S, T.C., M.K., N.E., and T.S. interpreted and

analyzed data.

H.H., Y.N., T.J., and T.C. wrote the paper; and H.S., M.K., D.H., N.E., T.F., N.I., T.S.,

and K.C. revised the paper.

All authors approved the paper.

25

Competing interest:

All authors do not have any personal or financial support or involvement with

organization(s) that have financial interest in the subject matter, or any competing

interest.

Funding:

This research received no specific grant from any funding agency in the public,

commercial or not-for-profit sectors.

Ethic approval:

Institutional review board in Hamamatsu University School of Medicine approved this

study (approval number 24-191) and waived patient approval or informed consent

because the study involved a retrospective review of patient records and images.

Copyright:

I *[Yutaro Nakamura*] the Corresponding Author of this article contained within the

original manuscript which includes any diagrams & photographs, other illustrative

material, video, film or any other material howsoever submitted by the Contributor(s) at

26

any time and related to the Contribution ("the Contribution") have the right to grant on

behalf of all authors and do grant on behalf of all authors, a licence to the BMJ

Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be

published in BMJ Open and any other BMJ Group products and to exploit all subsidiary

rights, as set out in the licence

27

Reference

1. Collard HR, Moore BB, Flaherty KR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2007;176:636-43.

2. Churg A, Wright JL, Tazelaar HD. Acute exacerbations of fibrotic interstitial lung disease. *Histopathology.* 2011;58:525-30.

3. Suda T, Kaida Y, Nakamura Y, et al. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases. *Respir Med.* 2009;103:846-53.

4. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest.* 2007;132:214-20.

5. Lee DM, Weinblatt ME. Rheumatoid arthritis. *Lancet.* 2001;358:903-11.

6. Tanoue LT. Pulmonary manifestations of rheumatoid arthritis. *Clin Chest Med.* 1998;19:667-85.

7. Turesson C, O'Fallon WM, Crowson CS, et al. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. *Ann Rheum Dis.* 2003;62:722–7.

8. Norton S, Koduri G, Nikiphorou E, et al. A study of baseline prevalence and cumulative incidence of comorbidity and extra-articular manifestations in RA and

28

their impact on outcome. Rheumatology (Oxford). 2013;52:99-110.

9. Carmona L, González-Alvaro I, Balsa A, et al. Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. *Ann Rheum Dis.* 2003;62:897–900.

10. Dawson JK, Fewins HE, Desmond J, et al. Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. *Thorax.* 2001;56:622–7.

11. Gabbay E, Tarala R, Will R, et al. Interstitial lung disease in recent onset rheumatoid arthritis. *Am J Respir Crit Care Med.* 1997;156:528–35.

12. Gochuico BR, Avila NA, Chow CK, et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis. *Arch Intern Med.* 2008;168:159–66.

13. Mori S, Cho I, Koga Y, et al. Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis. *J Rheumatol.* 2008;35:1513–21.

14. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum.* 1988;31:315-24.

29

15. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on

Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement:

idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and

management. *Am J Respir Crit Care Med.* 2011;183:788-824.

16. American Thoracic Society/European Respiratory Society International

Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.

Am J Respir Crit Care Med. 2002;165:277-304.

17. Hyzy R, Huang S, Myers J, et al. Acute exacerbation of idiopathic pulmonary

fibrosis. *Chest.* 2007;132:1652-8.

18. Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary

fibrosis: incidence, risk factors and outcome. *Eur Respir J.* 2011;37:356-63.

19. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung

disease: the relevance of histopathologic and radiographic pattern. *Chest.*

2009;136:1397-405.

20. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic,

and histopathologic features of methotrexate-associated lung injury in patients with

rheumatoid arthritis: a multicenter study with literature review. *Arthritis Rheum.*

1997;40:1829-37.

30

21. Alarcón GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced

lung injury in patients with rheumatoid arthritis. A multicenter, case-control study.

Methotrexate-Lung Study Group. *Ann Intern Med.* 1997;127:356-64.

22. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in

patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.*

2009;68:1100-4.

23. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the

literature and histopathological findings in nine patients. *Eur Respir J.*

2000;15:373-81.

24. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in

rheumatoid arthritis. *Rheumatology (Oxford).* 2004;43:143-7.

25. Nakamura Y, Suda T, Kaida Y, et al. Rheumatoid lung disease: prognostic analysis

of 54 biopsy-proven cases. *Respir Med.* 2012;106:1164-9.

26. Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. *Am

Rev Respir Dis.* 1985;131:770-7.

27. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of

rheumatoid arthritis-associated interstitial lung disease. *Chest.* 2005;127:2019-27.

28. Yoshinouchi T, Ohtsuki Y, Fujita J, et al. Nonspecific interstitial pneumonia pattern

31

as pulmonary involvement of rheumatoid arthritis. *Rheumatol Int.* 2005;26:121-5.

29. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. *Am J Respir Crit Care Med.* 2007;175:705-11.

30. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. *Eur Respir J.* 2010;35:1322-8.

31. Koduri G, Norton S, Young A, et al. ERAS (Early Rheumatoid Arthritis Study). Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. *Rheumatology (Oxford).* 2010;49:1483-9.

32

Table 1 Clinical characteristics

Characteristics	Total	Non-AE group[#]	AE group[¶]	P value[+]
	N = 51 (100)	N = 40 (78)	N = 11 (22)	
Median age, years (range)				
at RA diagnosis	61 (28-82)	60 (28-81)	65 (42-82)	0.15
at ILD diagnosis	62 (31-83)	62 (31-83)	69 (58-83)	0.15
at AE onset			72 (60-86)	
Sex Male, n (%)	29 (57)	23 (58)	6 (55)	0.86
Observation period, years (range)	8.5 (1-17)	9 (1-17)	6.4 (2-14)	0.45
AE-free period, years (range)	7(1-17)	9 (1-17)	6 (2-14)	0.19
Smoking habit, n (%)				
Never	20 (39)	18 (45)	2 (18)	
Former	24 (47)	16 (40)	8 (73)	0.15
Current	7 (14)	6 (15)	1 (9)	
RF, IU/mL (range)[*]	197 (6-2666)	189 (6-2666)	205 (39-2530)	0.47
DAS28-CRP, score (range)[*]	1.95(1.02-5.13)	2.53(1.02-5.13)	1.82(1.47-2.3)	0.62
PaO_2, torr (range)	82.4 (67-109)	81 (67-102)	85.8 (74-109)	0.19
%FVC, % (range)	91.1 (50.6-130)	87.5 (51-130)	95 (60-125)	0.38
HRCT pattern, n (%)				
UIP pattern	14 (27)	8 (20)	6 (55)	0.02[§]
non-UIP pattern	37 (73)	32 (80)	5 (45)	
Death during observation period, n (%)				
caused by respiratory failure	9 8 (18 16)	2 (5)	7 (64)	0.02[§]
caused by other diseases	3 4 (6 8)	3 (8)	0 (0)	

Data are presented as n (%), median (range). AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; RF, rheumatoid factor; DAS28-CRP, disease activity score 28 CRP; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; HRCT, high resolution computed tomography; UIP pattern, usual interstitial pneumonia pattern.

[#]Non-AE group, patients who did not develop AE during observation period.

[¶]AE group, patients who developed AE during observation period.

[+]Non-AE group vs AE group

[§] $p < 0.05$

[*] at the first AE occurrence (AE group) or the last visit (non-AE group).

When HRCT pattern was identified as a UIP pattern, the positive predictive value and negative predictive value for AE occurrence was 42.9% and 86.5%, respectively.

33

In the AE group, 7 patients died of respiratory failure caused by AE. In the non-AE group, 2 died of respiratory failure caused by bacterial pneumonia or pneumocystis pneumonia, 1 of gastric bleeding and 2 of unknown causes.

34

Table 2 Diagnostic accuracy of HRCT pattern for histopathological pattern in 21 histopathologically confirmed patients.

	Histopathological pattern		Total
	UIP	Other pattern	
UIP pattern on HRCT	5	0	5
non-UIP pattern on HRCT	7	9	16
Total	12	9	21

Data are presented as number.

HRCT, high resolution computed tomography; UIP, usual interstitial pneumonia.

Other pattern means other histopathological pattern except for UIP including nonspecific interstitial pneumonia, desquamative interstitial pneumonia and unclassifiable interstitial pneumonia.

~~When HRCT pattern was identified as a UIP pattern on HRCT, t~~The sensitivity, specificity, positive predictive value, and negative predictive value of HRCT for ~~detecting~~ histopathological evidence of UIP is~~was~~ 41.7%, 100%, 100% and 56.3%, respectively.

Table 3 Treatment for RA at final visit[#] or AE onset[¶]

	Total	non-AE group[+]	AE group[§]	P value
	N = 51	N = 40 (78%)	N = 11 (22%)	
Treatment, yes	37 (73)	27(68)	10 (91)	0.12
Corticosteroid	29 (57)	22 (55)	7 (64)	0.61
Immunosuppressant except for MTX	17 (33)	14 (35)	3 (27)	0.63
MTX	10 (20)	4 (10)	6 (55)	0.001[*]
Other drugs	17 (33)	13 (33)	4 (36)	0.81

Data are presented as n (%) and compared between non-AE group and AE group using Fisher's exact test.

Immunosuppressant except for MTX included azathioprine (n=1), cycrophosphaminde (n=1), etanercept (n=2), mizoribine (n=7), and tacrolimus (n=6).

Other drugs included actarit (n=2), bucillamine (n=5), meloxicam (n=1), and salazosulfapyridine (n=11).

AE, acute exacerbation; ILD, interstitial lung disease; MTX, methotrexate.

[#] In non-AE group.

[¶] In AE group.

[+] Non-AE group, patients who did not develop AE during the observation period.

[§] AE group, patients who developed AE during observation period.

[*] $p < 0.05$

36

Table 4 Risk factors for AE occurrence according to univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	1.03	0.97-1.10	0.35
Age at ILD diagnosis	1.11	1.02-1.21	0.01[+]
Sex, male	0.90	0.49-1.69	0.73
Smoking habit, yes	1.60	0.81-4.10	0.19
UIP pattern on HRCT, yes	1.95	1.07-3.63	0.03[+]
PaO_2 at ILD diagnosis	1.05	0.98-1.12	0.14
%FVC at ILD diagnosis	1.02	0.99-1.06	0.24
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	0.97	0.53-1.92	0.94
Immunosuppressant except for MTX	0.76	0.35-1.41	0.39
MTX	3.04	1.62-6.02	0.001[+]
Other drugs	0.98	0.50-1.80	0.96

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

37

Table 5 Prognostic factors for survival, univariate cox hazard analysis.

	HR	95%CI	P value
Age at RA diagnosis	0.98	0.93-1.04	0.48
Age at ILD diagnosis	1.08	0.99-1.17	0.057
Sex, male	1.14	0.63-2.22	0.67
Smoking habit, yes	1.70	0.87-4.35	0.13
UIP pattern on HRCT, yes	1.74	0.97-3.12	0.06
PaO_2 at ILD diagnosis	1.05	0.98-1.11	0.15
%FVC at ILD diagnosis	1.01	0.98-1.04	0.55
AE during observation period, yes	2.47	1.39-4.56	0.003[+]
Treatment for RA at final visit[#] or AE onset[¶]			
Corticosteroids	1.23	0.67-2.65	0.52
Immunosuppressant except for MTX	0.69	0.32-1.27	0.25
MTX	1.44	0.67-2.68	0.31
Other drugs	0.76	0.36-1.41	0.40

RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography; PaO_2, arterial oxygen pressure; %FVC, predicted forced vital capacity; AE, acute exacerbation; MTX, methotrexate; HR, hazard ratio; 95%CI, 95% confidence interval.

[#] In non-AE group.

[¶] In AE group.

[+] $p < 0.05$

38

Figure legends

Figure 1. Numbers of patients included in this study.

82 patients with RA-ILD were assessed for eligibility. From these, 31 patients were

excluded, and 51 patients with chronic course of RA-ILD were included. During

observation period, 11 patients developed AE.

RA, rheumatoid arthritis; ILD, interstitial lung disease; AE, acute exacerbation.

Figure 2. Cumulative AE incidence in patients with RA-ILD.

Patients with UIP pattern on HRCT had a significantly higher incidence of AE

compared with non-UIP pattern on HRCT (log-rank p=0.018).

AE, acute exacerbation; RA, rheumatoid arthritis; ILD, interstitial lung disease; UIP,

usual interstitial pneumonia; HRCT, high resolution computed tomography.

Figure 3. Overall survival and the survival according to HRCT pattern subgroup.

Patients with UIP pattern on HRCT had a significantly worse survival compared with

those with non-UIP pattern on HRCT (log-rank p=0.04).

UIP, usual interstitial pneumonia; HRCT, high resolution computed tomography.

39

Figure 4. Survival of AE group and non-AE group.

Patients who developed AE during observation periods (AE group) had a significantly

worse survival compared with those who did not (non-AE group) (log-rank *p*=0.001).

AE, acute exacerbation.

40